Antibodies to programmed cell death protein 1 as PD-1 agonists
By specifically binding to PD-1, the antibody and antigen-binding fragments that specifically bind to PD-1, act as PD-1 agonists, activate immune cells, solving the problem of poor effectiveness of existing PD-1/PD-L1 blocking therapy, significantly enhancing the immune response and T cell activation improve cancer treatment effect.
Patent Information
- Application Number
- CN202380029518.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-11-19
AI Technical Summary
The existing PD-1/PD-L1 blocking therapy fails to provide effective immune responses to most cancer patients, resulting in poor treatment results and lack of in-depth research on predictive biomarkers.
Develop antibodies and antigen-binding fragments specifically bound to PD-1, as PD-1 agonists, activate PD-1 independently of disrupting PD-1/PD-L1 interactions, promote the proliferation and activation of immune cells, through A specific amino acid sequence binds to PD-1 away from the interaction site, delivering activation signals.
Significantly enhance or promote immune response, activate T cells, inhibit T cell depletion, and enhance T cell memory, improve therapeutic effects, and have therapeutic potential for cancer and infection.
Smart Images

Figure BDA0005054790230000261 
Figure BDA0005054790230000271 
Figure BDA0005054790230000281
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 304,365, filed on January 28, 2022, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present invention generally relates to antibodies that specifically bind to PD-1 and methods of using the same. Background Art
[0004] The programmed cell death receptor protein 1 (PD-1) / programmed cell death receptor protein ligand 1 (PD-L1) pathway has shown promising clinical success as a cancer immunotherapy target. Antibodies that disrupt this pathway by physically inhibiting the interaction between PD-1 and PD-L1 can enhance patients' immune responses against cancer cells. For example, pembrolizumab ( Merck & Co., Inc., Kenilworth, NJ) binds to amino acids 64-89 in human PD-1, which overlaps with the portion of PD-1 that PD-L1 binds to. (Zak et al., Cell Structure 25(8):1163-1174 (2017)). Successful clinical trials of PD-1 monoclonal antibodies and other immune checkpoint inhibitors have opened up new avenues for cancer immunology. However, most cancer patients fail to respond to new immunotherapies (including blocking anti-PD1 therapies), leading to in-depth research on combination therapies and predictive biomarkers (Iwai, Y. et al. Journal of Biomedical Science,
[0005] Therefore, it is desirable to provide compositions and methods for modulating PD-1 signaling. It is particularly desirable to provide compositions and methods that act as PD-1 agonists, i.e., activate PD-1 independently of disrupting the PD-1 / PD-L1 interaction.
[0006] It is also desirable to provide antibodies and antigen-binding fragments thereof that specifically bind to PD-1 and modulate PD-1 signal transduction. It is particularly desirable to provide antibodies and antigen-binding fragments that act as PD-1 agonists, i.e., activate PD-1 independently of disrupting the PD-1 / PD-L1 interaction.
[0007] It would also be desirable to provide compositions and methods for treating cancer.
[0008] It would also be desirable to provide compositions and methods for treating infections. Summary of the invention
[0009] The present disclosure relates to antibodies and antigen-binding fragments thereof that immunospecifically bind to PD-1 (ideally human or mouse PD-1) and are PD-1 agonists. Such antibodies can be used to induce or promote immune responses that activate the proliferation or activity of immune cells. In an embodiment, the disclosed antibodies and antigen-binding fragments thereof specifically bind to PD-1 expressed on immune cells. In a specific embodiment, the disclosed antibodies and antigen-binding fragments thereof specifically bind to a PD-1 epitope that is away from the site of interaction between PD-1 and PD-L1 (e.g., not located at amino acid residues within the range of 64-89 in human PD-1). In a specific embodiment, the antibody or antigen-binding fragment does not compete with PD-L1 for binding to PD-1. The binding of the disclosed antibodies and antigen-binding fragments thereof to PD-1 on immune cells can result in activation signals being transmitted to immune cells, such as signals that enhance or promote cytokine production and / or immune cell proliferation activation. Immune cells expressing PD-1 include, but are not limited to, B and T cells and myeloid cells (Riley, J., Immunol Rev..229(1); 114-125 - (2009)). In an embodiment, the immune cell is a T cell, ideally a CD8 + T cells.
[0010] The present disclosure also relates to a method of stimulating, promoting or enhancing an immune response (e.g., an adaptive immune response) in a subject in need thereof, by administering to the subject an effective amount of an anti-PD-1 antibody or an antigen-binding fragment thereof as disclosed herein to induce, enhance or promote an immune response (e.g., an adaptive immune response) in the subject.
[0011] An antibody or antigen-binding fragment thereof having binding specificity to programmed cell death receptor protein 1 (PD-1) may comprise a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR L1, CDR L2 and CDRL3 from Table 2 or Table 4, and the heavy chain variable region comprises CDR H1, CDR H2 and CDR H3 from Table 1 or Table 3.
[0012] In an embodiment, an antibody or antigen-binding fragment thereof having binding specificity to programmed cell death receptor protein 1 (PD-1) may comprise a light chain variable region and a heavy chain variable region, wherein a) the light chain variable region comprises a QX 8 X 9 X 10 X 11 X 12 CDR L1, containing X 13 X 14 CDR L2 of S and containing X 15 QX 16 X17 X 18 X 19 PX 20 X 21 The heavy chain variable region comprises a CDR L3 comprising GYTFTTYG (SEQ ID NO: 394), a CDR H1 comprising INTYSGVP (SEQ ID NO: 395), and a CDR H2 comprising ARX 1 X 2 X 3 X 4 X 5 X 6 X 7 CDR H3, where X 1 Selected from the group consisting of G and V; X 2 Selected from the group consisting of G, S, L, V, I and E; X 3 Selected from the group consisting of R, G, P, W, S, H and K; X 4 Selected from the group consisting of G, E, S, V, W and K; X 5 Selected from the group consisting of I, F, S, G, D and V; X 6 Selected from the group consisting of A, G, Y and S; X 7 Selected from the group consisting of Y, H and D; X 8 Selected from the group consisting of G, S and D; X 9 Selected from the group consisting of I and L; X 10 Selected from the group consisting of S, V, G and R; X 11 Selected from the group consisting of N, Y, T, S and R; X 12 Selected from the group consisting of S, Y, D and W; X 13 Selected from the group consisting of A, K, Y and D; X 14 Selected from the group consisting of A and V; X 15 Selected from the group consisting of Q, M and L; X 16 Selected from the group consisting of S, G and D; X 17 Selected from the group consisting of Y, T, N and S; X 18 Selected from the group consisting of S, H and D; X 19 Selected from the group consisting of T, W and F; X 20 is selected from the group consisting of Y, P, R and W; and X 21 selected from the group consisting of T and F; or b) the light chain variable region comprises QX 42 X 43 X 44 X 45 X 46 CDR L1, containing X 47 CDRL2 and containing X 48 X49 X 50 X 51 X 52 X 53 X 54 CDR L3, and the heavy chain variable region contains GX 22 TFX 23 X 24 YX 25 (SEQ ID NO: 163), CDR H1 containing IX 26 X 27 X 28 X 29 X 30 X 31 T CDR H2 and containing AX 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 FX 40 X 41 CDR H3, where X 22 Selected from the group consisting of Y and Q; X 23 Selected from the group consisting of N, T and G; X 24 Selected from the group consisting of S, I and N; X 25 Selected from the group consisting of W and L; X 26 Selected from the group consisting of H, L, R and P; X 27 Selected from the group consisting of P and L; X 28 Selected from the group consisting of R, S, I and N; X 29 Selected from the group consisting of G, D, N and Y; X 30 Selected from the group consisting of I, S, G and R; X 31 Selected from the group consisting of H, D and Y; X 32 Selected from the group consisting of P and S; X 33 Selected from the group consisting of S, R, N and Y; X 34 Selected from the group consisting of S, D, G, V and F; X 35 Selected from the group consisting of S, N, G, I, D and R; X 36 Selected from the group consisting of Y, N, C, L, S and H; X 37 Selected from the group consisting of A, G, T and E; X 38 Selected from the group consisting of W, C, S, R, D and G; X 39 Selected from the group consisting of A, S, G and D; X 40 Selected from the group consisting of A, S and L; X 41 Selected from the group consisting of H, Y and S; X42 Selected from the group consisting of D, S and G; X 43 Selected from the group consisting of V and I; X 44 Selected from the group consisting of S and G; X 45 Selected from the group consisting of T and S; X 46 Selected from the group consisting of A, S, D and W; X 47 Selected from the group consisting of W, G and D; X 48 Selected from the group consisting of Q and H; X 49 Selected from the group consisting of Q, K and H; X 50 Selected from the group consisting of H, Y, F, R, D and G; X 51 Selected from the group consisting of Y, N, Y, D, S and G; X 52 Selected from the group consisting of R, S, V, T and I; X 53 is selected from the group consisting of S, A, F, T, Y and W; and X 54 Selected from the group consisting of P, L, S and T.
[0013] In an embodiment, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-12; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-1; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-2; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-4; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-5; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-6 L3, CDRH1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-7; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-8; CDR L1, CDR L2, CDR L3, CDRH1, CDR of 4G9-9 H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-10; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-11; CDR L1, CDR L2, CDR L3, CDRH1, CDR H2 and CDR of 4G9-13 H3; CDR of 4G9-14 L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-15; CDR L1, CDR L2, CDR L3, CDRH1, CDR H2 and CDR H3 of 4G9-16; CDR L1, CDR of 4G9-17 L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-18; CDR L1, CDR L2, CDR L3, CDRH1, CDR H2 and CDR H3 of 4G9-19; CDR L1, CDR L2, CDR of 4G9-20 L3, CDR H1, CDR H2 and CDR H3;CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-1; CDR L1, CDR L2, CDR L3, CDRH1, CDR H2 and CDR H3 of 5C2-2; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-3; CDR of 5C2-4 L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDRH1, CDR H2 and CDR H3 of 5C2-5; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-6; CDR L1, CDR L2, CDR of 5C2-7 L3, CDR H1, CDR H2 and CDR H3 of 5C2-8; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-9; or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-10. In a specific embodiment, the antibody or antigen-binding fragment comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12; or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-2. Antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10 are described herein. In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12. ;
[0014] In an embodiment, the antibody or antigen-binding fragment comprises the light chain variable region and heavy chain variable region of 4G9-12; the light chain variable region and heavy chain variable region of 4G9-1; the light chain variable region and heavy chain variable region of 4G9-2; the light chain variable region and heavy chain variable region of 4G9-3; the light chain variable region and heavy chain variable region of 4G9-4; the light chain variable region and heavy chain variable region of 4G9-5; the light chain variable region and heavy chain variable region of 4G9-6 region; the light chain variable region and heavy chain variable region of 4G9-7; the light chain variable region and heavy chain variable region of 4G9-8; the light chain variable region and heavy chain variable region of 4G9-9; the light chain variable region and heavy chain variable region of 4G9-10; the light chain variable region and heavy chain variable region of 4G9-11; the light chain variable region and heavy chain variable region of 4G9-13; the light chain variable region and heavy chain variable region of 4G9-14; the light chain variable region and heavy chain variable region of 4G9-15 region and heavy chain variable region; the light chain variable region and heavy chain variable region of 4G9-16; the light chain variable region and heavy chain variable region of 4G9-17; the light chain variable region and heavy chain variable region of 4G9-18; the light chain variable region and heavy chain variable region of 4G9-19; the light chain variable region and heavy chain variable region of 4G9-20; the light chain variable region and heavy chain variable region of 5C2-1; the light chain variable region and heavy chain variable region of 5C2-2; and the light chain variable region and heavy chain variable region of 5C2- 3; 5C2-4; 5C2-5; 5C2-6; 5C2-7; 5C2-8; 5C2-9; or 5C2-10. In a specific embodiment, the antibody or antigen-binding fragment thereof comprises the light chain variable region and heavy chain variable region of 4G9-12. In a specific embodiment, the antibody or antigen-binding fragment thereof comprises the light chain variable region and heavy chain variable region of 4G9-2.
[0015] One embodiment provides an antibody or antigen-binding fragment thereof, wherein CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 are each independently at least 75% identical to the corresponding CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10, such as at least 85% identical or at least 90% identical. In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each of which is independently at least 75% identical to the corresponding CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12, such as at least 85% identical or at least 90% identical.
[0016] One embodiment provides an antibody or antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, each independently having at least 75% identity, such as at least 85% identity, at least 90% identity, or at least 95% identity, with the corresponding light chain variable region and heavy chain variable region of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10. In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, each independently having at least 75% identity, such as at least 85% identity, at least 90% identity, or at least 95% identity, with the corresponding light chain variable region and heavy chain variable region of 4G9-12.
[0017] One embodiment provides an antibody or antigen-binding fragment thereof, wherein CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have three or fewer amino acid substitutions, such as two amino acid substitutions or one amino acid substitution, relative to the corresponding CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0018] The antibodies or antigen-binding fragments thereof of the present disclosure may further comprise a light chain constant region or a portion thereof and / or a heavy chain constant region or a portion thereof, for example, the heavy chain constant region may be an IgG constant region.
[0019] The antibodies or antigen-binding fragments thereof disclosed herein can increase the phosphorylated interleukin-2 inducible T cell kinase (pITK) level, ITK / SHP2 ratio, or both the pITK level and ITK / SHP2 ratio in the cell when bound to PD-1 on the cell. By activating T cells, the antibodies or antigen-binding fragments thereof disclosed herein can induce T cell memory and / or inhibit T cell exhaustion. In one embodiment, an antibody or antigen-binding fragment thereof induces central memory T cells (Tcm). In one embodiment, an antibody or antigen-binding fragment thereof inhibits T cell exhaustion.
[0020] The present disclosure also relates to polynucleotides encoding the heavy chain, light chain, or both of the above antibodies or antigen-binding fragments thereof.
[0021] The present disclosure relates to a host cell comprising a polynucleotide. In embodiments, the host cell is a mammalian cell (e.g., a human cell, a CHO cell, an immortalized human cell, a NS0 cell). In a specific embodiment, the host cell can be a cell of a transgenic animal. In embodiments, the transgenic animal is a mouse.
[0022] The present disclosure also relates to a pharmaceutical composition comprising the above antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier.
[0023] One embodiment provides an antibody or epitope-binding fragment or fusion protein thereof that immunospecifically binds to a PD-1 epitope comprising amino acids 96-110 of human PD-1 (hPD-1). In certain preferred embodiments, the antibody or antigen-binding fragment binds to a PD-1 epitope comprising amino acids 96-110 of hPD-1 expressed on the surface of an immune cell. Without being bound by any particular theory or mechanism, it is believed that binding of the antibody or antigen-binding fragment to this epitope of PD-1 induces or promotes a signal through PD-1 that activates or stimulates immune cells without disrupting the PD-1 / PD-L1 interaction. In an embodiment, the activated or stimulated immune cell is a T cell, such as a CD4 T cell.
[0024] In embodiments, the antibody or antigen-binding fragment thereof can be human, murine, chimeric, humanized, monoclonal, bispecific, trispecific, or multispecific.
[0025] The present disclosure also relates to a pharmaceutical composition comprising one or more of the disclosed antibodies or antigen-binding fragments thereof. The pharmaceutical composition may include a second therapeutic agent and / or a pharmaceutically acceptable excipient. In an embodiment, the second therapeutic agent may be a second antibody or antigen-binding fragment thereof that reduces the inhibition of PD-L1 on PD-1.
[0026] The present disclosure also relates to a method for treating cancer, comprising administering an effective amount of an antibody, antigen binding fragment or pharmaceutical composition as described herein to a subject in need thereof. The present disclosure also relates to antibodies, antigen binding fragments or pharmaceutical compositions disclosed herein for use as medicaments (e.g., particularly cancer therapy) and for treating cancer and / or for the manufacture of medicaments for treating cancer.
[0027] The disclosed method of treatment may also include administering one or more additional therapeutic agents to the subject. One or more additional therapeutic agents may be immunomodulators. Immunomodulators may be checkpoint inhibitors (e.g., checkpoint inhibitors, provided that the checkpoint inhibitors do not inhibit the interaction of PD-1 with PD-L1 or PD-L2). For example, checkpoint inhibitors may be anti-LAG-3 antibodies or antigen binding fragments thereof. As another example, checkpoint inhibitors may be anti-CTLA4 antibodies or antigen binding fragments thereof. Immunomodulators may be T cell conjugates, including bispecific T cell conjugates (BiTE), bifunctional checkpoint inhibitory T cell conjugates (CiTE), synchronous multi-interaction T cell conjugates (SMITE), trispecific killer cell conjugates (TriKE), chimeric antigen receptor (CAR) T cells expressing BiTE (CART.BiTE cells) and combinations thereof.
[0028] One or more additional therapeutic agents can be cell therapy. For example, cell therapy can be T cell therapy. Cell therapy can be tumor infiltrating lymphocytes (TIL). Cell therapy can be engineered cell therapy, such as engineered TCR therapy, chimeric antigen receptor (CAR) therapy or a combination thereof. In one embodiment, cell therapy is a chimeric antigen receptor T cell (CAR-T cell). In one embodiment, cell therapy is an engineered TCR T cell (TCR-T cell). For example, the method may include administering an effective combination to a subject, the effective combination comprising a therapeutically effective amount of (i) an antibody or antigen binding fragment as described herein as a PD-1 agonist and (ii) a second antibody or its antigen binding fragment that reduces the suppression of PD-L1 to PD-1. Although not bound by theory, the second antibody or antigen binding fragment can be bound to PD-1 or PD-L1 at a position that physically interferes with the interaction between PD-1 and PD-L1. In another example, the method can include administering to the subject an effective combination comprising a therapeutically effective amount of (i) an antibody or antigen-binding fragment that is a PD-1 agonist as described herein and (ii) an immune checkpoint inhibitor that does not bind to PD-1 or PD-L1, such as anti-CTLA4 or anti-LAG-3.
[0029] The present disclosure also relates to a method for inducing or enhancing central memory T cells, comprising administering a therapeutically effective amount of the antibody or antigen-binding fragment disclosed herein to a subject in need thereof.
[0030] The present disclosure further relates to a method for inhibiting T cell exhaustion, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment disclosed herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1A and Figure 1B is a graph showing activation of human T cells from two donors as determined by interferon gamma (IFNγ) levels according to Example 3 for antibodies 4G9-2 and 4G9-12. Figure 1A is a graph showing IFNγ levels following activation of human T cells from donor 1 without agonist anti-PD-1 antibody ('control'), with 4G9-2, or with 4G9-12 at concentrations of 0 and 10 μg / mL of the antibody. Figure 1B is a graph showing IFNγ levels following activation of human T cells from donor 2 without agonist anti-PD-1 antibody ('control'), with 4G9-2 antibody, or with 4G9-12 antibody at concentrations of 0, 10, 20, and 50 μg / mL antibody. IFNγ levels without agonist anti-PD-1 antibody treatment are shown as a dotted line for comparison.
[0032] Figure 2 The results show that the antibodies 4G9-1 to 4G9-10 according to Example 4 were expressed as human CD4 + Figure 1 shows T cell activation and also shows that 4G9-2 treatment significantly increased IFNγ (*p<0.05) compared to the non-affinity matured antibody ('4G9 HC4-LC1'). The lower dotted line represents the average IFNγ level in cells not treated with 4G9 lineage antibodies ("untreated"). The upper dotted line represents the average IFNγ level in cells treated with non-affinity matured antibodies ("4G9 HC4-LC1").
[0033] Figure 3A-3C is shown to characterize responses to human CD4 + Schematic diagram and graphs showing the design and results of experiments with memory T cells and terminal effector T cell populations treated with an agonist antibody to T cells (4G9-12). Figure 3A is a schematic diagram of the experiment described in Example 5. Figure 3B It shows that after 4G9-12 treatment, central memory T cells (CD45RO 高 / CD62L 高 / CD45RA 低 ) accounts for CD4 +Graph of the percentage of T cells. Figure 3C The terminal effector T cells (CD45RO 低 / CD62L 低 / CD45RA 高 ) accounts for CD4 + Graph of the percentage of T cells.
[0034] Figure 4A-4C The results show that in the study described in Example 6, anti-PD1 agonist antibodies, but not isotype controls or PD-1 blocking antibodies, have an effect on CD4 + Diagram of T cell stimulation. Figure 4A The results showed that donor CD4 + T cells, diagram of activated T cells and induced IFNγ production. Figure 4B The second donor CD4 + T cells, diagram of activated T cells and induced IFNγ production. Figure 4C The results are shown in Figure 2. The third donor CD4+ T cells were treated with increasing concentrations of 4G9-12 antibody but not with an isotype control antibody (“Iso Ctrl”), a blocking anti-PD-1 antibody (PROMEGA Co., clone J1201, “Blocking-1”), or pembrolizumab (blocking anti-PD-1 antibody, “Blocking-2”). + T cells, diagram of activated T cells and induced IFNγ production.
[0035] Figure 5 The present invention shows that treatment of human CD4+ T cells with an anti-PD-1 agonist antibody (4G9-2) and PD-L1 (e.g., PD-L1-IgG) and 4G9-2 but not PD-L1 (e.g., PD-L1-IgG) or a blocking anti-PD-1 antibody increases the expression of IFNγ as measured by IFNγ release compared to cells not treated with the antibody or ligand ("untreated"). + T cells increased a graph of T cell activation. The results showed that even in the presence of PD-L1, anti-PD-1 agonist antibodies significantly increased T cell activation, as assessed by IFNγ release. Further experimental details are described in Example 7.
[0036] Figure 6A-6C is a histogram showing the flow cytometry results of the competitive binding experiment between PD-L1 and agonist anti-PD-1 antibody (4G9-12) as described in Example 8. Fig. 6AShown is the dose-dependent binding of PD-L1 to PD-1 on the cell surface (PD-L1 fluorescence channel) at 1 μg / mL, 2 μg / mL, and 5 μg / mL PD-L1. Figure 6B It was shown that the binding of 4G9-12 (5 μg / ml) to cellular PD-1 was not affected by different PD-L1 concentrations. Figure 6C It was shown that the dose-dependent binding of PD-L1 to PD1 on the cell surface was not affected by the presence of 4G9-12 (5 μg / mL).
[0037] Figure 7 is a graph showing that following intraperitoneal (ip) treatment with 4G9-12 (0.5 mg / kg or 1.0 mg / kg) and to a lesser extent a blocking anti-PD-1 antibody (1.0 mg / kg, RMP1-14 clone), mean tumor volume was reduced in a syngeneic mouse model of colorectal cancer compared to untreated mice ("untreated") in the study described in Example 9.
[0038] Figure 8A-8D Yes Display Figure 7 and a graph of tumor volume per mouse in a syngeneic mouse model of colorectal cancer as further described in Example 9. Fig. 8A is a graph showing the tumor volume of each mouse in the untreated group. Figure 8B is a graph showing the tumor volume per mouse in the 4G9-12 antibody (1 mg / kg) group. Figure 8C is a graph showing the tumor volume per mouse in the 4G9-12 antibody (0.5 mg / kg) group. Fig.8D is a graph showing the tumor volume of each mouse in the blocking anti-PD-1 antibody (1 mg / kg, RMP1-14 clone) group.
[0039] Fig. 9 is a graph showing the reduction in mean tumor volume in the CT26 mouse model of colorectal cancer following intravenous (iv) treatment with 4G9-12 (0.01 mg / kg, 0.05 mg / kg, 0.1 mg / kg or 0.25 mg / kg) or blocking anti-PD-1 antibody (1.0 mg / kg, RMP1-14 clone) as further described in Example 10 compared to untreated mice ("untreated").
[0040] Figures 10A-10F Yes Display Fig. 9 Graph of tumor volume per mouse in the CT26 mouse model of colorectal cancer as described further in Example 10. Fig. 10A is a graph showing the tumor volume of each mouse in the untreated group. Fig. 10BIt is a graph showing the tumor volume of each mouse in the 4G9-12 antibody (0.01 mg / kg) group. Fig. 10C It is a graph showing the tumor volume of each mouse in the 4G9-12 antibody (0.05 mg / kg) group. Fig. 10D It is a graph showing the tumor volume per mouse in the 4G9-12 antibody (0.1 mg / kg) group. Fig.10E is a graph showing the tumor volume per mouse in the 4G9-12 antibody (0.25 mg / kg) group. Fig.10F is a graph showing the tumor volume of each mouse in the blocking anti-PD-1 antibody (1 mg / kg, RMP1-14 clone) group.
[0041] Fig.11A and Fig. 11B The results showed that in vivo treatment with 4G9-12 (anti-PD1 agonist antibody) but not with a blocking anti-PD-1 antibody (RMP1-14) significantly increased CD4 + T cells and CD8 + Diagram of T cell activation status, as further described in Example 11. Fig.11A The results showed that treatment with 4G9-12 (anti-PD1 agonist antibody) but not blocking anti-PD-1 antibody (RMP1-14) significantly increased CD4 + Diagram of T cell activation status (using CD40L as a marker of activation status). Fig. 11B It was shown that treatment with 4G9-12 (anti-PD1 agonist antibody) but not blocking anti-PD-1 antibody (RMP1-14) significantly increased CD8 + Diagram of T cell activation status (using CD25 as a marker of activation status). Statistical analysis included one-way ANOVA and multiple comparison post-test.
[0042] Figure 12A-12C is a Western blot and bar graph showing that treatment of human CD4+ T cells with agonist anti-PD-1 antibody 4G9-12 but not blocking anti-PD-1 antibody (PROMEGA Co., “Control”) or PD-L1 (e.g., PD-L1-IgG) + After incorporation of the in vitro T cells, the intracellular ratio of ITK to SHP2 increased, as further described in Example 12. Fig. 12A are images of western blots of SHP2 and PD-1. Fig. 12B are images of Western blot staining of PD-1 and ITK (interleukin-2-induced T-cell kinase). Fig. 12CBar graph of quantified ITK / SHP2 protein ratios. Values were normalized to PD-1 protein levels.
[0043] Fig.13 It is a graph of normalized mean fluorescence intensity (MFI) obtained by flow cytometry showing that treatment with agonist anti-PD-1 antibody 4G9-12 (25 μg / mL), but not with PD-L1 (e.g., PD-L1-IgG), pembrolizumab ("Pembro") or nivolumab ("Nivo"), increased phosphorylated interleukin-2-inducible T cell kinase (pITK) in CD4+ T cells compared to cells stimulated only without additional treatment ("Stim"), as further described in Example 13. The data are normalized to the "Stim" group that was stimulated only. The mean of the stimulated group is represented by a dotted line. Statistical analysis included one-way ANOVA and multiple comparison post-test. DETAILED DESCRIPTION
[0044] I. Definitions
[0045] As used herein, an antibody or antigen-binding fragment thereof is said to "immunospecifically bind" to a target region or conformation ("epitope") of an antigen if such binding involves the antigen recognition site of the antibody or antigen-binding fragment. Other antigens may be identified if they have some sequence or conformational similarity that is recognized by the antigen recognition site, such as by, for example, immunoassays, An antibody that immunospecifically binds to a specific epitope of a specific antigen may bind to other epitopes and / or antigens with lower affinity, provided that the antibody (and antigen-binding fragment thereof) will not cross-react with other antigens and / or epitopes, as determined by the ELISA or other assays known in the art, but will not bind to completely unrelated antigens. However, ideally, the antibody (and antigen-binding fragment thereof) will not cross-react with other antigens and / or epitopes. Antibodies and antigen-binding fragments may also bind to other molecules, such as to FcR receptors, in a non-immunospecific manner, by means of binding domains in other regions / domains of the molecule that are not involved in the antigen recognition site, such as the Fc region.
[0046] As used herein, the term "antibody" is intended to mean an immunoglobulin molecule having at least one "variable region" antigen recognition site comprising a heavy chain variable region and a light chain variable region. An antibody also has at least one constant domain that does not include an antigen recognition site.
[0047] The variable region includes a "hypervariable region" whose residues are responsible for antigen binding. The hypervariable region includes amino acid residues from a "complementarity determining region" or "CDR" (i.e., generally at approximately residues 24-34 (CDR L1), 50-56 (CDR L2), and 89-97 (CDR L3) in the light chain variable domain and approximately residues 27-35 (CDR H1), 50-65 (CDR H2), and 95-102 (CDRH3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)) and / or those residues from a "hypervariable loop" (i.e., residues 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk; 1987, J. Mol. Biol. 196:901-917). "Framework region" or "FR" residues are those variable region residues other than the hypervariable region residues defined herein. Other well-known amino acid numbering conventions can be used to define CDR and FR regions, such as the AHo scheme and the Chothia scheme.
[0048] The term antibody includes all types or antibodies from any desired species, such as monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies (see, e.g., Muyldermans et al., 2001, Trends Biochem. Sci. 26:230; Nuttall et al., 2000; Cur. Plum, Biotech. 1:253; Reichmann and Muyldermans, 1999, J. Immunol. Meth, 231:25; International Publication Nos. WO 94 / 04678 and WO 94 / 25591; U.S. Pat. No. 0305,079), single-chain Fv (scFv) (see, e.g., Pluckthun in The Pharmacology of Monoclonal. Antibodies, Vol. 113, Rosenburg and Moore, eds. Springer-Verlag, New York, pp. 269-315 (1994)), single-chain antibodies, disulfide-linked Fv (sdFv), intracellular antibodies, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies and anti-anti-Id antibodies directed against antibodies). Specifically, such antibodies include immunoglobulin molecules of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgGA2), or subclass.
[0049] As used herein, the term "antigen-binding fragment" of an antibody refers to one or more portions of an antibody that contain the complementarity determining region ("CDR") of an antibody and optional framework residues comprising the "variable region" antigen recognition site of an antibody and exhibit the ability to immunospecifically bind to an antigen. Such fragments include Fab', F(ab')2, Fv, single chain (ScFv), single variable domain (dAb), etc., and mutants, naturally occurring variants, and fusion proteins thereof, including the "variable region" antigen recognition site of an antibody and a heterologous protein (e.g., toxins, antigen recognition sites of different antigens, enzymes, receptors or receptor ligands, etc.).
[0050] As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 consecutive amino acid residues, such as at least 10 consecutive amino acid residues, at least 15 consecutive amino acid residues, at least 20 consecutive amino acid residues, at least 25 consecutive amino acid residues, at least 40 consecutive amino acid residues, at least 50 consecutive amino acid residues, or at least 60 consecutive amino acid residues. 个contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 1.25 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues or at least 250 contiguous amino acid residues.
[0051] As used herein, the term "modulation" refers to the ability to change an effect, result or activity (e.g., signal transduction). Such modulation can be agonistic or antagonistic. Antagonistic modulation can be partial (i.e., attenuated but not eliminated), or it can completely eliminate such activity (e.g., neutralization). Modulation can include the internalization of the receptor after binding to the antibody or the reduction of receptor expression on the target cell. Agonistic modulation can enhance or otherwise increase or enhance activity (e.g., signal transduction). In another embodiment, such modulation can change the nature of the interaction between the ligand and its cognate receptor, thereby changing the nature of the signal transduction triggered. For example, a molecule can change the ability of such a molecule to bind to other ligands or receptors by binding to a ligand or receptor, thereby changing their overall activity. Ideally, such modulation will provide at least a 10% change in measurable immune system activity; more ideally, at least a 50% change in such activity, or at least a 2-fold, 5-fold, 10-fold change, or more ideally, at least a 100-fold change in such activity.
[0052] The term "substantially" as used in the context of binding or showing an effect is intended to mean that the observed effect is physiologically or therapeutically relevant. Thus, for example, a molecule is capable of substantially blocking the activity of a ligand or receptor if the extent of blocking is physiologically or therapeutically relevant (e.g., if such extent is greater than 60% complete, greater than 70% complete, greater than 75% complete, greater than 80% complete, greater than 85% complete, greater than 90% complete, greater than 95% complete, or greater than 97% complete. Similarly, a molecule has substantially the same immunospecificity and / or characteristics as another molecule if such immunospecificity and characteristics are greater than 60% identical, greater than 70% identical, greater than 75% identical, greater than 80% identical, greater than 85% identical, greater than 90% identical, greater than 95% identical, greater than 97% identical, greater than 98% identical, or greater than 99% identical.
[0053] As used herein, the term "derivative" refers to an antibody or antigen-binding fragment thereof that immunospecifically binds to the same target of a parent or reference antibody, but differs from the parent or reference antibody or antigen-binding fragment thereof in amino acid sequence by including one, two, three, four, five or more amino acid substitutions, additions, deletions or modifications relative to the parent or reference antibody or antigen-binding fragment thereof. Ideally, such derivatives will have substantially the same immunospecificity and / or characteristics as the parent or reference antibody or antigen-binding fragment thereof, or the same immunospecificity and characteristics. The amino acid substitutions or additions of such derivatives may include naturally occurring (i.e., DNA-encoded) or non-naturally occurring amino acid residues. The term "derivative" includes, for example, chimeric or humanized variants, as well as variants with altered CH1, hinge, CH2, CH3 or CH4 regions, thereby forming, for example, antibodies with variant Fc regions that exhibit enhanced or reduced effectors or binding characteristics, etc.
[0054] As used herein, a "chimeric antibody" is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules, such as an antibody having variable regions derived from a non-human antibody and human immunoglobulin constant regions.
[0055] As used herein, the term "humanized antibody" refers to an immunoglobulin comprising a human framework region and one or more CDRs from a non-human (e.g., mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR is referred to as a "donor," and the human immunoglobulin providing the framework is referred to as an "acceptor." Constant regions are not required, but if present, they should be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-99%, ideally about 95% or more identical. Therefore, all parts of the humanized immunoglobulin, except possible CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A humanized antibody is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody will not include a typical chimeric antibody, because, for example, the entire variable region of a chimeric antibody is non-human.
[0056] As used herein, "therapeutically effective amount" refers to the amount of therapeutic agent that is sufficient to mediate clinically relevant elimination, alleviation or improvement of these symptoms under the conditions of administration. An effect is clinically relevant if the magnitude of the effect is sufficient to affect the health or prognosis of the recipient subject. A therapeutically effective amount may refer to an amount of therapeutic agent that is sufficient to delay or minimize the progression or onset of a disease, such as delaying or minimizing the spread or progression of a cancer. A therapeutically effective amount may also refer to the amount of a therapeutic agent that provides a therapeutic benefit in the treatment or control of a disease.
[0057] As used herein, "immune cell" refers to any cell of hematopoietic origin, including but not limited to T cells, B cells, monocytes, dendritic cells, and macrophages.
[0058] The terms "subject" and "patient" are used interchangeably herein and refer to mammals, including but not limited to humans, pets (e.g., cats, dogs), livestock and sport animals (e.g., cattle, sheep, horses, camels), rodents (such as mice and rats), and other experimental animals, etc.
[0059] As used herein, the term "variant" refers to a polypeptide or polynucleotide that is different from a reference polypeptide or polynucleotide but retains basic properties. A typical variant of a polypeptide is different from another reference polypeptide in amino acid sequence. Usually, the difference is limited, so the sequences of the reference polypeptide and the variant are generally very similar and identical in many regions. The variant and the reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions and / or deletions). The substituted or inserted amino acid residue may or may not be an amino acid residue encoded by the genetic code. The variant of a polypeptide may be naturally occurring, such as an allelic variant, or it may be an unknown naturally occurring variant.
[0060] Modifications and changes can be made in the structure of the polypeptides of the present disclosure and still obtain a molecule with similar characteristics to the polypeptide (e.g., conservative amino acid substitutions). For example, certain amino acids can replace other amino acids in the sequence without significant loss of activity. Because the interaction ability and properties of the polypeptide define the biological functional activity of the polypeptide, certain amino acid sequence substitutions can be made in the polypeptide sequence and still obtain a polypeptide with similar properties.
[0061] In making such changes, the hydropathic index of the amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biological function on polypeptides is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids with similar hydropathic indexes or scores and still produce polypeptides with similar biological activity. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics. Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8.); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (1.3); proline (-1.6); histidine (-3,2); glutamate (-3.5); glutamine (-3.5); aspartic acid (-3,5); asparagine (-3.5); lysine (-3.9); and arginine (4.5).
[0062] Although not being bound by theory, the relative hydrophilicity of amino acids determines the secondary structure of the resulting polypeptide, which in turn determines the interaction of the polypeptide with other molecules (such as enzymes, substrates, receptors, antibodies, antigens and cofactors). It is known in the art that an amino acid can generally be substituted with another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, substitution of amino acids with a hydropathic index within +2 is desirable, those with a hydropathic index within ±1 are particularly desirable, and those with a hydropathic index within ±0.5 are even more particularly desirable.
[0063] Substitution of similar amino acids may also be made on the basis of hydrophilicity, particularly where the resulting biologically functional equivalent polypeptide or peptide is intended for use in immunological embodiments. The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid - (+3.0 ± 1); glutamic acid (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (-0.5. ± 1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (4.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It should be understood that one amino acid can be substituted for another amino acid having a similar hydrophilicity value and still obtain a biologically equivalent, particularly an immunologically equivalent, polypeptide. In such changes, substitution of amino acids whose hydrophilicity values are within ±2 is desirable, those within ±1 are particularly desirable, and those within ±0.5 are even more particularly desirable.
[0064] As described above, amino acid substitutions are generally based on the relative similarity of the amino acid side chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into account various of the foregoing characteristics are well known to those of skill in the art and include (original residue → exemplary substitutions): (Ala → Gly, Ser), (Arg → Lys), (Asn → Gln, His), (Asp → Gln, Cys, Ser), (Gln → Asn), (Glu → Asp), (Gly → Ala), (His → Asn, Gln), (Ile → Leu, Val), (Leu → Ile, Val), (Lys → Arg), (Met → Leu, Tyr), (Ser → Thr), (Thr → Ser), (Trp → Tyr); (Tyr → Trp, Phe) and (Val → Ile, Leu). Therefore, embodiments of the present disclosure contemplate functional or biological equivalents of the polypeptides described above. In particular, embodiments of the polypeptides may include variants having about 75% or more, such as 80%, 90% or 95% or more sequence identity to the polypeptide of interest.
[0065] The term "sequence identity percentage (%)" is defined as the percentage of nucleotides or amino acids in the candidate sequence that are identical to those in the reference nucleic acid sequence, after the sequences are aligned and, if necessary, gaps are introduced to obtain the maximum sequence identity percentage. The comparison for determining the sequence identity percentage can be accomplished in various ways within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, SIM or Megalign (DNASTAR) software. Suitable parameters for measuring the comparison can be determined by known methods, including any algorithm designed for achieving maximum comparison over the full length of the compared sequence.
[0066] For the purposes of this document, the percent sequence identity of a given nucleotide or amino acid sequence C to a given nucleic acid sequence D (which may alternatively be expressed as a given sequence C having or comprising a certain % sequence identity to a given sequence D) is calculated as follows:
[0067] 100*W / Z,
[0068] Where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in the program's alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be understood that when the length of sequence C is not equal to the length of sequence D, the % sequence identity of C to D will not be equal to the % sequence identity of D to C.
[0069] As used herein, the term "pharmaceutically acceptable carrier" includes any standard pharmaceutical carriers, such as phosphate buffered saline solutions, water, and emulsions (such as oil / water or water / oil emulsions), as well as various types of wetting agents.
[0070] II. Composition
[0071] Provided are antibodies and antigen-binding fragments thereof that immunospecifically bind to PD-1. Contrary to the main paradigm of anti-PD-1 antibodies used as "checkpoint inhibitors" that reduce the suppression of PD-L1 activity by PD-1 at the time of writing (Riley, J., Immunol Rev. 229 (1): 114-125 (2009)), the disclosed antibodies and antigen-binding fragments thereof immunospecifically bind to an epitope of PD-1 away from the PD-L1 interaction site, and are PD-1 agonists, and cause activation signals to be delivered to immune cells. The anti-PD-1 agonist antibodies and antigen-binding fragments disclosed herein not only inhibit T cell suppression, but also activate T cells. As shown and illustrated herein, the PD-1 agonists disclosed herein can activate T cells, inhibit T cell exhaustion, and enhance T cell memory in addition to inhibiting T cell suppression. In contrast, anti-PD-1 antibodies that block PD-L1 binding (e.g., non-agonist PD-1 antibodies) act as checkpoint inhibitors, and a recognized disadvantage of checkpoint inhibitors is that they may cause T cell exhaustion and may reduce T cell memory.
[0072] A. Programmed death receptor protein 1 (PD-1)
[0073] The disclosed antibodies and antigen-binding fragments thereof immunospecifically bind to PD-1. The antibodies and antigen-binding fragments thereof may bind to PD-1 having, for example, an amino acid sequence provided below.
[0074] Human PD-1 (UniProtKB Q15116)
[0075] MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNATFTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPNGRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARRTGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPSGMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL(SEQ ID NO:396)
[0076] Mouse PD-1 (UniProtKB Q02242)
[0077] MWVRQVPWSFTWAVLQLSWQSGWLLEVPNGPWRSLTFYPAWLTVSEGANATFTCSLSNWSEDLMLNWNRLSPSNQTEKQAAFCNGLSQPVQDARFQIIQLPNRHDFHMNILDTRRNDSGIYLCGAISLHPKAKIEESPGAELVVTERILETSTRYPSPSPKPEGRFQGMVIGIMSALVGIPVLLLLAWALAVFCSTSMSEARGAGSKDDTLKEEPSAAPVPSVAYEELDFQGREKTPELPTACVHTEYATIVFTEGLGASAMGRRGSADGLQGPRPPRHEDGHCSWPL(SEQ ID NO:397)
[0078] Preferably, the antibody or its antigen-binding fragment binds to PD-1 and is an agonist of PD-1. In a specific embodiment, the antibody and antigen-binding fragment of the present disclosure bind to an epitope of PD-1 that is not part of the PD-1 structure that interacts with PD-L1. In a specific embodiment, the antibody and antigen-binding fragment immunospecifically bind to a PD-1 epitope comprising amino acids 96-110 of hPD-1, which has an amino acid sequence of TYLCGAISLAPKAQI (SEQ ID NO: 398). The epitope is described in more detail in US11,021,540, which is incorporated herein by reference in its entirety. Although not bound by theory, it is believed that the immunospecific binding of the antibody or antigen-binding fragment of the present disclosure to the PD-1 epitope comprising amino acids 96-110 of hPD-1 activates PD-1-mediated signal transduction.
[0079] B. Antibody Composition
[0080] The disclosed anti-PD-1 antibodies or antigen-binding fragments thereof include any class of whole immunoglobulins (i.e., antibodies comprising two heavy chains and two light chains), fragments thereof, and proteins containing at least the antigen-binding variable regions of antibodies. In some embodiments, the disclosed antibodies contain both antibody light chain variable regions and antibody heavy chain variable regions. In other embodiments, such molecules may also include one or more of the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. The antibody may be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA, and IgE, and any isotype, including IgG1, IgG2, IgG3, and IgG4. In some embodiments, the constant domain is a complement binding constant domain, in which the antibody is expected to exhibit cytotoxic activity, and the class is typically IgG1. In other embodiments where such cytotoxic activity is not required, the constant domain may belong to the IgG2 or IgG4 class. The antibody may include sequences from more than one class or isotype, and selecting a specific constant domain to optimize the desired effector function is within the scope of those of ordinary skill in the art.
[0081] The variable regions of natural heavy and light chains each contain four FW regions, mainly in a β-sheet configuration, connected by three CDRs, forming a loop connecting the β-sheet structure, and in some cases forming a part of the β-sheet structure. The CDRs in each chain are bound together in a dose-closed manner by the FW region, and together with the CDRs from the other chain, contribute to the formation of the antibody antigen binding site.
[0082] Some embodiments provide antigen-binding fragments of anti-PD-1 antibodies. These fragments, whether or not attached to other sequences, may include insertions, deletions, substitutions or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the unmodified antibody or antibody fragment (e.g., antigen-binding fragment).
[0083] Another embodiment provides a single-chain antibody specific for PD-1. Methods for producing single-chain antibodies are well known to those skilled in the art. Single-chain antibodies can be produced by fusing the variable regions of the heavy and light chains together using a short peptide linker, thereby reconstructing the antigen binding site on a single molecule. Single-chain antibody variable region fragments (scFv) have been developed, in which the C-terminus of one variable region is connected to the N-terminus of another variable region via a peptide or linker of 15 to 25 amino acids without significantly destroying the specificity of antigen binding or binding. The linker is selected to allow the heavy and light chains to be combined together in their appropriate conformational orientation.
[0084] Another embodiment provides a divalent single-chain variable fragment (di-ScFv), which can be engineered by connecting two scFv. This can be achieved by producing a single peptide chain with two VH and two VL regions, thereby producing a series of scFv. ScFv can also be designed to have a linker peptide, which is so short that the two variable regions cannot fold together (about five amino acids), forcing scFv dimerization. This type is called a diabody. The dissociation constant of the diabody has been shown to be at most 40 times lower than the corresponding scFv, which means that they have a much higher affinity to their target. Shorter linkers (one or two amino acids) lead to the formation of trimers (triabodies / tribodies). Tetrabodies have also been produced. Compared with diabodies, they show higher affinity to targets.
[0085] Another embodiment provides a monoclonal antibody specific for PD-1 that induces activation signals for immune cells. Monoclonal antibodies can be obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies in the population are identical except for possible naturally occurring mutations that may be present in a small subset of antibody molecules. Monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired activity.
[0086] C. Chimeric and humanized antibodies
[0087] Another embodiment provides chimeric anti-PD-1 antibodies and antigen-binding fragments thereof, which include one or more of the disclosed sequences, and also provides functional variants thereof, which bind to PD-1 and preferably cause activation signals to be transmitted to immune cells expressing PD-1.
[0088] Methods for producing chimeric antibodies are known in the art. See, for example, Morrison, 1985, Science 229:1202; Oi et al., 1986, BioTechniques 4:214; Gillies et al., 1989, J. Immunol. Methods 125:191-202; and U.S. Pat. Nos. 6,311,415, 5,807,715, 4,816,567, and 4,816,397. Chimeric antibodies comprising one or more CDRs from a non-human species and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art, including, for example, CDR grafting (EP 239,400; International Publication No. WO91109967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering 7;805; and Roguska et al., 1994, Proc. Natl. Acad. Sci. USA 91:969) and chain shuffling (U.S. Pat. No. 5,565,332).
[0089] The disclosed anti-PD-1 antibodies or antigen-binding fragments thereof may be human or humanized antibodies, or antigen-binding fragments thereof. Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans and therefore can cause an undesirable immune response when administered to humans. Therefore, the use of human or humanized antibodies in this method reduces the chance that antibodies administered to humans will cause an undesirable immune response.
[0090] Transgenic animals (e.g., mice) that can produce all human antibodies when immunization is performed without endogenous immunoglobulin production can be used. For example, homozygous deletions of antibody heavy chain joining region (J (H)) genes in chimeric and germline mutant mice have been described to result in complete inhibition of endogenous antibody production. Transferring human germline immunoglobulin gene arrays in such germline mutant mice will result in the production of human antibodies when antigens are attacked. Suitable expression or display libraries, such as phage display, can also be used to produce such antibodies.
[0091] Optionally, antibodies are generated in other species and are "humanized" for human use. The humanized form of non-human (e.g., mouse) antibodies is a chimeric immunoglobulin, an immunoglobulin chain or its fragment (such as Fv, Fab, Fab', F(ab')2 or other antigen binding subsequences of an antibody), which comprises the minimum sequence derived from a non-human immunoglobulin. Humanized antibodies include human immunoglobulins (receptor antibodies), wherein the residues from the complementary determining regions (CDRs) of the receptor antibodies are replaced by the residues from the CDRs of non-human species (donor antibodies) (such as mice, rats or rabbits) with required specificity, affinity and ability. In some cases, the Fv framework residues of human immunoglobulins are replaced by corresponding non-human residues. Humanized antibodies can also contain residues that are neither present in the receptor antibodies nor in the CDRs or framework sequences of the input. Generally speaking, humanized antibodies will contain substantially all of at least one and usually two variable regions, wherein all or substantially all of the CDR regions correspond to the CDR regions of non-human immunoglobulins, and all or substantially all of the FW regions are the FW regions of human immunoglobulin consensus sequences. Humanized antibodies may also optimally contain at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin.
[0092] Methods for humanizing non-human antibodies are well known in the art, see, e.g., European Patent Nos. EP 239,400, EP 592,106, and EP 519,596; International Publication Nos. WO 91 / 09967 and WO 93 / 17105; U.S. Pat. Nos. 5,225,539, 5,530,101, 5,565,332, 5,585,089, 5,766,886, and 6,407,213; and Padlan, 1991, Molecular immunology 28(4 / 5):489-498: Studnicka et al., 1994, Protein Engineering 7(6):805-8.1:4; Roguska et al., 1994, PNAS 91:969,973; Tan et al., 2002, J. Immunol. 169:1119-1125; Caldas et al., 2000, Protein Eng. 13:353-360; Motet et al., 2000, Methods 20:267-79; Baca et al., 1997, J. Mot Chem. 272:1067840684; Roguska et al., 1996, Protein Eng. 9:895-904; Couto et al., 1995, Cancer Res. 55(23 Suppl):5973s-5977s; Couto Oat, 1995, Cancer. Res. 55:1717-22; Sandhu, 1994, Gene 150:409-10; Pedersen et al., 1994, 1 Mat Riot 235:959-973; Jones et al., 1986, Nature 321:522, 525; Reichmann et al., 1988, Nature 332:323, 329; and Presta, 1992 (Curr. Op. Struct. Biol. 2:593-596).
[0093] Generally, humanized antibodies have one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are generally referred to as "input" residues, which are usually taken from "input" variable regions. Antibody humanization techniques generally involve DNA sequences that use recombinant DNA technology to operate one or more polypeptide chains encoding antibody molecules. Humanization can essentially be achieved by replacing the corresponding sequences of human antibodies with rodent CDR or CDR sequences. Therefore, the humanized form of non-human antibodies (or their fragments) is a chimeric antibody or fragment, wherein substantially less than complete human variable regions are replaced by corresponding sequences from non-human species. In practice, humanized antibodies are usually human antibodies, in which some CDR residues and possible FW residues are replaced by residues from similar sites in rodent antibodies.
[0094] In order to reduce antigenicity, the selection of people's light chain variable region and heavy chain variable region for the preparation of humanized antibodies is very important. According to the "best fit" method, the variable region sequence of rodent antibodies is screened for the whole library of known people's variable region sequences. Then the people's sequence closest to the rodent sequence is accepted as the people's framework (FW) of humanized antibodies. Another method uses the specific framework of the consensus sequence of all human antibodies of the specific subgroup derived from light chain or heavy chain. The same framework can be used for several different humanized antibodies.
[0095] More importantly, the antibody is humanized and retains high affinity to antigen and other favorable biological properties. In order to achieve this goal, humanized antibodies can be prepared by using the three-dimensional model of the parental sequence and the humanized sequence to analyze the method of the parental sequence and various conceptual humanized products. The three-dimensional immunoglobulin model is usually available and is familiar to those skilled in the art. Computer programs are available, and they illustrate and display the possible three-dimensional conformational structure of selected candidate immunoglobulin sequences. Inspection of these displays allows analysis of the possible effects of residues in the function of candidate immunoglobulin sequences, i.e., analysis of the residues that affect the ability of candidate immunoglobulins to bind their antigens. In this way, FW residues can be selected and combined from consensus sequences and input sequences to obtain desired antibody characteristics, such as an increase in affinity to the target antigen.
[0096] The present disclosure also relates to a chimeric antigen receptor (CAR), which comprises a light chain variable region and a heavy chain variable region of any antibody or antigen binding fragment disclosed herein. CAR is a well-known transmembrane receptor that can be expressed on T cells, providing T cell activation by the desired antigen in an MHC-independent manner. Typically, CAR includes a scFv with the desired binding specificity, which is fused to a hinge region hinge (e.g., and IgG hinges, CD28 hinges, CD8α hinges with or without CH domains from IgG1, IgG2 or IgG4), a transmembrane domain (e.g., CD28 transmembrane domain and cytoplasmic tail), a CD3ζ cytoplasmic domain, and optionally one or more costimulatory domains (e.g., 4-1BB, OX40, CD28). In an embodiment, the CAR comprises the light chain variable region of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10 and the heavy chain variable region of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0097] People, humanized or chimeric antibody derivatives can include substantially all at least one and usually two variable regions, wherein all or substantially all CDR regions correspond to the CDR regions of non-human immunoglobulins (i.e., donor antibodies), and all or substantially all framework regions are framework regions of human immunoglobulin consensus sequences. Such antibodies can also include at least a portion of immunoglobulin constant regions (Fc), typically the constant regions of human immunoglobulins. The constant domains of such antibodies can be selected according to the expected function of the antibody, particularly the effector functions that may be required. In some embodiments, the constant domains of such antibodies are or may include human IgA, IgD, IgE, IgG or IgM domains. In a specific embodiment, when humanized antibody derivatives are intended for therapeutic use and antibody effector functions (such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity) are required, human IgG constant domains, especially constant domains of IgG1 and IgG3 isotypes are used. In alternative embodiments, when antibodies are intended for therapeutic purposes and antibody effector functions are not required, IgG2 and IgG4 isotypes are used. The Fc constant domain includes one or more amino acid modifications that alter antibody effector function, such as those disclosed in US Patent Application Publication Nos. 2005 / 0037000 and 200510004514.
[0098] The framework region and CDR region of humanized antibody do not need to accurately correspond to the parent sequence, for example, donor CDR or common framework can be induced by substitution, insertion or deletion of at least one residue (for example, at least two residues, at least three residues, at least four residues, at least five residues, at least six residues, at least seven residues, at least eight residues), so that the CDR or framework residues at this site neither correspond to the common antibody nor to the donor antibody. In some embodiments, the difference between CDR and parent sequence is the substitution, insertion or deletion of one residue, two residues, three residues or four residues. In some embodiments, the difference between framework region and parent sequence is the substitution, insertion or deletion of one residue, two residues, three residues, four residues, five residues, six residues, seven residues or eight residues. In some embodiments, such mutation is not extensive. Generally, at least 75% of humanized antibody residues will correspond to the residues of parent framework region (FW) and CDR sequence, such as at least 80%, at least 90% or at least 95%. Generally, the framework residues in framework region will be replaced by the corresponding residues from CDR donor antibody, to change (for example, improve) antigen binding. These framework substitutions are identified by methods well known in the art, such as by modeling the interactions of CDR and framework residues to identify framework residues important for antigen binding, and by sequence comparison to identify unusual framework residues at specific positions (see, e.g., Queen et al., U.S. Pat. No. 5,585,089; U.S. Publication Nos. 2004 / 0049014 and 2003 / 0229208; U.S. Pat. Nos. 6,350,861; 6,180,370; 5,693,762; 5;693,761; 5,585,089 and 5,530,101 and Riechmann et al., 1988, Nature 332:323).
[0099] In an embodiment, the antibody or antigen-binding fragment is a human antibody or fragment, i.e., only comprising human sequences. Such human antibodies or antigen-binding fragments may be particularly desirable for therapeutic therapies of human subjects. Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences (see U.S. Patents No. 4,444,887 and No. 4,716,111; and International Publications No. WO 98 / 46645, No. WO 94 / 50433, No. WO 98 / 24893, No. WO 98 / 16654, No. WO 96 / 34096, No. WO 96 / 33735 and No. WO 91 / 10741). Such human antibodies can be produced using transgenic mice that cannot express functional endogenous immunoglobulins but can express human immunoglobulin genes.
[0100] For example, human heavy chain and light chain immunoglobulin gene complexes can be introduced into mouse embryonic stem cells randomly or by homologous recombination. Alternatively, in addition to human heavy chain and light chain genes, human variable regions, constant regions, and diversity regions can also be introduced into mouse embryonic stem cells. Mouse heavy chain and light chain immunoglobulin genes can be introduced into human immunoglobulin loci separately or simultaneously by homologous recombination and become non-functional. Specifically, J H Homozygous deletion of the region prevents the production of endogenous antibodies. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then cultivated to produce homozygous offspring expressing human antibodies. Transgenic mice can be immunized with selected antigens (e.g., all or part of a polypeptide) using conventional methods. Monoclonal antibodies against the antigen can be obtained from immunized transgenic mice using conventional hybridoma technology. The human immunoglobulin transgene carried by the transgenic mice is rearranged during B cell differentiation; and sulue4yettly undergoes class switching and somatic mutation. Therefore, using this technology, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar 1995, Int. Rev. Immunol. 13: 65-93, which is incorporated herein by reference in its entirety). For a detailed discussion of such techniques for generating human antibodies and human monoclonal antibodies and protocols for generating such antibodies, see, e.g., International Publication Nos. WO 98 / 24893; WO 96 / 34096 and WO 96433735; and U.S. Pat. Nos. 5,413,923, 5,625,126, 5,633,425, 5,569,825, 5,661,016, 5,545,806, 5,814,318 and 5,939,598, the entireties of which are incorporated herein by reference.
[0101] DNA sequences encoding human receptor framework sequences include, but are not limited to, FW segments from human germline VH segments VH1-18 and JH6 and human germline VL segments VK-A26 and JK4. In a specific embodiment, conventional recombinant DNA techniques can be used to insert one or more CDRs into the framework region. The framework region can be a naturally occurring or shared framework region, as well as a human framework region. For a list of human framework regions, see, for example, Chothia et al., 1998, "Structural Determinants In The Sequences Of Immunoglobulin Variable Domain," J. Mol. Biol. 278: 457-479.
[0102] D. Fusion protein
[0103] In an embodiment, an antibody or antigen binding fragment can be a component of a fusion protein or a fusion polypeptide, wherein the antibody or antigen binding fragment can be coupled to another polypeptide, such as a chimeric antigen receptor (CAR). A fusion polypeptide has a first fusion partner that is covalently bound to a second polypeptide directly or via a connecting peptide sequence that is covalently bound to a second polypeptide, and the first fusion partner includes all or part of one or more disclosed antibodies or antigen binding fragments. A fusion protein may, but need not necessarily, contain a domain that serves to dimerize or multimerize two or more fusion proteins. A peptide / polypeptide joint domain may be a separate domain, or alternatively may be included in one of the other domains (antibody / antigen binding fragment or second polypeptide) of a fusion protein. Similarly, a domain (if any) that serves to dimerize or multimerize a fusion protein may be a separate domain, or may be included in one of the other domains (antibody / antigen binding fragment, second polypeptide or joint domain) of a fusion protein. In an embodiment, a dimerization / multimerization domain and a peptide / polypeptide joint domain are identical.
[0104] The fusion proteins disclosed herein may, for example, have Formula I:
[0105] N-R1-R2-R3-C (I)
[0106] Wherein N represents the N-terminus of the fusion protein, C represents the C-terminus of the fusion protein, R1 can be all or part of one of the disclosed antibodies, antigen-binding fragments, or functional variants or fragments thereof, R2 is an optional peptide / polypeptide linker domain, and R3 can be a second polypeptide. Alternatively, R3 can be all or part of one of the disclosed antibodies, antigen-binding fragments, or functional variants or fragments thereof, and R1 can be a second polypeptide.
[0107] Dimerization or multimerization can occur between two or more fusion proteins through a dimerization or multimerization domain. Alternatively, the dimerization or multimerization of the fusion protein can occur through chemical cross-linking. The dimer or multimer formed can be a homodimer / homomultimer or a heterodimer / heteromultimer.
[0108] E. Antibody Sequences
[0109] 1.4G9 and 5C2 sequences
[0110] One embodiment of the present disclosure relates to affinity matured antibodies or antigen binding fragments thereof, which are derived from humanized antibodies isolated from hybridoma 4G9. Specifically, the embodiment provides antibodies and antigen binding fragments comprising sequences found in or related to the sequences of twenty antibodies named 4G9-1 to 4G9-20. The heavy chain variable region (VH), CDR H1, CDR H2 and CDR H3 sequences of each of these antibodies are given in Table 1.
[0111] Antibodies 4G9-1, 4G9-2, 4G9-3, 4G9-4, 4G9-5, 4G9-6, 4G9-7, 4G9-8, 4G9-9 and 4G9-10 contain the same heavy and light chain CDRs as antibodies 4G9-11, 4G9-12, 4G9-13, 4G9-14, 4G9-15, 4G9-16, 4G9-17, 4G9-18, 4G9-19 and 4G9-20, respectively. In addition, the light chain variable regions of 4G9-1, 4G9-2, 4G9-3, 4G9-4, 4G9-5, 4G9-6, 4G9-7, 4G9-8, 4G9-9 and 4G9-10 are identical to the light chain variable regions of 4G9-11, 4G9-12, 4G9-13, 4G9-14, 4G9-15, 4G9-16, 4G9-17, 4G9-18, 4G9-19 and 4G9-20, respectively. However, the heavy chain variable regions of 4G9-1, 4G9-2, 4G9-3, 4G9-4, 4G9-5, 4G9-6, 4G9-7, 4G9-8, 4G9-9 and 4G9-10 are different from the heavy chain variable regions of 4G9-11, 4G9-12, 4G9-13, 4G9-14, 4G9-15, 4G9-16, 4G9-17, 4G9-18, 4G9-19 and 4G9-20, respectively, and each of 4G9-11, 4G9-12, 4G9-13, 4G9-14, 4G9-15, 4G9-16, 4G9-17, 4G9-18, 4G9-19 and 4G9-20 includes an N73D substitution.
[0112] Table 1. VH, CDR H1, CDR H2 and CDR H3 sequences of antibodies 4G9-1 to 4G9-20
[0113]
[0114]
[0115]
[0116]
[0117]
[0118] In ARX 1 X2 X 3 X 4 X 5 X 6 X 7 In, X 1 Selected from the group consisting of G and V; X 2 Selected from the group consisting of G, S, L, V, I and E; X 3 Selected from the group consisting of R, G, P, W, S, H and K; X 4 Selected from the group consisting of G, E, S, V, W and K; X 5 Selected from the group consisting of I, F, S, G, D and V; X 6 is selected from the group consisting of A, G, Y and S; and X 7 Selected from the group consisting of Y, H and D.
[0119] The light chain variable region (VK), CDR L1, CDR L2 and CDR L3 sequences of each of these antibodies are given in Table 2.
[0120] Table 2. VK, CDR L1, CDR L2 and CDR L3 sequences of antibodies 4G9-1 to 4G9-20
[0121]
[0122]
[0123]
[0124]
[0125] In QX 8 X 9 X 10 X 11 X 12 , X 13 X 14 S and X 15 QX 16 X 17 X 18 X 19 PX 20 X 21 In, X 8 Selected from the group consisting of G, S and D; X 9 Selected from the group consisting of I and L; X 10 Selected from the group consisting of S, V, G and R; X 11 Selected from the group consisting of N, Y, T, S and R; X 12 Selected from the group consisting of S, Y, D and W; X 13 Selected from the group consisting of A, K, Y and D; X 14 Selected from the group consisting of A and V; X15 Selected from the group consisting of Q, M and L; X 16 Selected from the group consisting of S, G and D; X 17 Selected from the group consisting of Y, T, N and S; X 18 Selected from the group consisting of S, H and D; X 19 Selected from the group consisting of T, W and F; X 20 is selected from the group consisting of Y, P, R and W; and X 21 Selected from the group consisting of T and F.
[0126] One embodiment of the present disclosure relates to affinity matured antibodies or antigen binding fragments thereof, which are derived from humanized antibodies isolated from hybridoma 5C2. Specifically, the embodiment provides antibodies and antigen binding fragments comprising sequences found in or related to the sequences of twenty antibodies named 5C2-1 to 5C2-10. The heavy chain variable region (VH), CDR H1, CDR H2 and CDR H3 sequences of each of these antibodies are given in Table 3.
[0127] Table 3. VH, CDR H1, CDR H2 and CDR H3 sequences of antibodies 5C2-1 to 5C2-10
[0128]
[0129]
[0130]
[0131]
[0132] In GX 22 TFX 23 X 24 YX 25 (SEQ ID NO: 163), IX 26 X 27 X 28 X 29 X 30 X 31 T and AX 32 X 33 X 34 X 35 X 36 X 37 X 38 X 3 9 FX 40 X 41 In, X 22 Selected from the group consisting of Y and Q; X 23 Selected from the group consisting of N, T and G; X 24 Selected from the group consisting of S, I and N; X25 Selected from the group consisting of W and L; X 26 Selected from the group consisting of H, L, R and P; X 27 Selected from the group consisting of P and L; X 28 Selected from the group consisting of R, S, I and N; X 29 Selected from the group consisting of G, D, N and Y; X 30 Selected from the group consisting of I, S, G and R; X 31 Selected from the group consisting of H, D and Y; X 32 Selected from the group consisting of P and S; X 33 Selected from the group consisting of S, R, N and Y; X 34 Selected from the group consisting of S, D, G, V and F; X 35 Selected from the group consisting of S, N, G, I, D and R; X 36 Selected from the group consisting of Y, N, C, L, S and H; X 37 Selected from the group consisting of A, G, T and E; X 38 Selected from the group consisting of W, C, S, R, D and G; X 39 Selected from the group consisting of A, S, G and D; X 40 Selected from the group consisting of A, S and L; X 41 Selected from the group consisting of H, Y and S.
[0133] The light chain variable region (VK), CDR L1, CDR L2 and CDR L3 sequences of each of these antibodies are given in Table 4.
[0134] Table 4. VK, CDR L1, CDR L2 and CDR L3 sequences of antibodies 5C2-1 to 5C2-10
[0135]
[0136]
[0137]
[0138] In QX 42 X 43 X 44 X 45 X 4 6. X 47 AS and X 48 X 49 X 50 X 51 X 52 X 53 X 54 In, X 42 Selected from the group consisting of D, S and G; X 43 Selected from the group consisting of V and I; X 44Selected from the group consisting of S and G; X 45 Selected from the group consisting of T and S; X 46 Selected from the group consisting of A, S, D and W; X 47 Selected from the group consisting of W, G and D; X 48 Selected from the group consisting of Q and H; X 49 Selected from the group consisting of Q, K and H; X 50 Selected from the group consisting of H, Y, F, R, D and G; X 51 Selected from the group consisting of Y, N, Y, D, S and G; X 52 Selected from the group consisting of R, S, V, T and I; X 53 is selected from the group consisting of S, A, F, T, Y and W; and X 54 Selected from the group consisting of P, L, S and T.
[0139] In an embodiment, an antibody or antigen-binding fragment thereof having binding specificity to programmed cell death receptor protein 1 (PD-1) comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region contains any CDR L1 of Table 2 or Table 4, any CDR L2 of Table 2 or Table 4, and any CDR L3 of Table 2 or Table 4, and the heavy chain variable region contains any CDR H1 of Table 1 or Table 3, any CDR H2 of Table 1 or Table 3, and any CDR H3 of Table 1 or Table 3.
[0140] In an embodiment, an antibody or antigen-binding fragment thereof that has binding specificity to programmed cell death receptor protein 1 (PD-1) comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region contains CDR L1, CDR L2, and CDR L3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10, and the heavy chain variable region contains CDR H1, CDR H2, and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0141] In an embodiment, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-1; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-2; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-3. each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-4; each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-5. H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-6; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-7; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of 4G9-8;CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-9; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-10; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-11; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-12. CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-13; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-14. H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-15; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-16; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-17 L2, CDR L3, CDR H1, CDR H2 and CDR H3;each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-18; each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-19; each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 4G9-20. CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-1; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-2. CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-4; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-5 L3, CDR H1, CDR H2 and CDR H3;each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-6; each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-7; each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-8. CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-9; or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each having an amino acid sequence that is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94% or at least about 95% identical to the amino acid sequence of the corresponding CDR of 5C2-10. ;
[0142] In an embodiment, the antibody or antigen-binding fragment thereof is defined by CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each of which independently has at least 75% identity, such as at least 85% identity or at least 90% identity, to the corresponding CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0143] In an embodiment, the antibody or antigen-binding fragment thereof comprises CDRL1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence identical to the sequence of the corresponding CDR of 4G9-1 or containing one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDRL2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence identical to the sequence of the corresponding CDR of 4G9-2 or containing one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence identical to the sequence of the corresponding CDR of 4G9-3 or containing one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence identical to the sequence of the corresponding CDR of 4G9-4 or containing one or two amino acid substitutions, insertions or deletions compared to the sequence. CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-5 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-6 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-7 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-8 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-9 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence;CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-10 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-11 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-12 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-13 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-14 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-15 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-16 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-17 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-18 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDRL1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-19 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence;CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have an amino acid sequence that is identical to the sequence of the corresponding CDR of 4G9-20, or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-1, or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-2, or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-3, or contains one or two amino acid substitutions, insertions or deletions compared to the sequence CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-4 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-5 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3, each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-6 or contains one or two amino acid substitutions, insertions or deletions compared to the sequence H3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-7 or contains one or two amino acid substitutions, insertions or deletions compared to that sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-8 or contains one or two amino acid substitutions, insertions or deletions compared to that sequence; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence that is identical to the sequence of the corresponding CDR of 5C2-9 or contains one or two amino acid substitutions, insertions or deletions compared to that sequence;or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently having an amino acid sequence identical to the sequence of the corresponding CDR of 5C2-10 or containing one or two amino acid substitutions, insertions or deletions compared to the sequence. In the aforementioned embodiment, it is preferred that each CDR independently has an amino acid sequence identical to the reference CDR, or contains one amino acid substitution, insertion or deletion relative to the reference CDR. In the aforementioned embodiment, it is preferred that each of the one or two substitutions, insertions or deletions is a substitution that is a conservative substitution. ;
[0144] In a specific embodiment, the antibody or antigen-binding fragment comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-2. In another specific embodiment, the antibody or antigen-binding fragment comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12.
[0145] In some embodiments, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, which each independently have at most one deletion, insertion, or substitution compared to CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0146] In some embodiments, the antibody or antigen-binding fragment thereof comprises CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3, each of which independently has up to two deletions, insertions, or substitutions compared to CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0147] An embodiment provides an antibody or antigen-binding fragment thereof, wherein CDRL1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 each independently have three or fewer amino acid substitutions, such as two amino acid substitutions or one amino acid substitution, relative to the corresponding CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0148] In an embodiment, the antibody or antigen-binding fragment comprises a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-1; each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-2. light chain variable region and heavy chain variable region that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-3; light chain variable region and heavy chain variable region that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-4. variable region and a heavy chain variable region; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-5; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-6. chain variable regions; light chain variable regions and heavy chain variable regions that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-7; light chain variable regions and heavy chain variable regions that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-8;a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-9; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-10; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-11; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-12; a light chain variable region and a heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-13; a light chain variable region and a heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-14; a light chain variable region and a heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-15; a light chain variable region and a heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-16;A light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-17; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-18. ; light chain variable regions and heavy chain variable regions, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-19; light chain variable regions and heavy chain variable regions, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-20. light chain variable region and heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-1; light chain variable region and heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-2. ; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-3; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-4;light chain variable regions and heavy chain variable regions that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 5C2-5; and light chain variable regions and heavy chain variable regions that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 5C2-6. light chain variable regions and heavy chain variable regions that have at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-7; light chain variable regions and heavy chain variable regions that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-7; each light chain variable regions and heavy chain variable regions that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-8; light chain variable regions and heavy chain variable regions that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-9; 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity; or light chain variable regions and heavy chain variable regions each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-10.;
[0149] For example, a preferred antibody or antigen-binding fragment may comprise a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-2; and a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-4. light chain variable region and heavy chain variable region that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-8; light chain variable region and heavy chain variable region that have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-9. region and a heavy chain variable region; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-12; a light chain variable region and a heavy chain variable region, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the corresponding light chain and heavy chain variable region sequences of 4G9-14. variable regions; light chain variable regions and heavy chain variable regions, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-18; light chain variable regions and heavy chain variable regions, each having at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 4G9-19;or a light chain variable region and a heavy chain variable region that each have at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity to the corresponding light chain and heavy chain variable region sequences of 5C2-8. While not being bound by theory, the exemplary antibodies or antigen-binding fragments of this paragraph have the desired PD-1 agonist activity. ;
[0150] In a specific embodiment, the antibody or antigen-binding fragment thereof comprises the light chain variable region and the heavy chain variable region of 4G9-2. In a specific embodiment, the antibody or antigen-binding fragment thereof comprises the light chain variable region and the heavy chain variable region of 4G9-12.
[0151] In embodiments, the antibodies or antigen-binding fragments comprise a light chain variable region and a heavy chain variable region that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23, or at most 24 deletions, insertions, or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-1; and each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23, or at most 24 deletions, insertions, or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-2. at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11 deleted, inserted or substituted light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-3. , at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-4. at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-5;light chain variable region and heavy chain variable region that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-6; light chain variable region and heavy chain variable region that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-7 , up to five, up to six, up to seven, up to eight, up to nine, up to ten, up to 11, up to 12, up to 13, up to 14, up to 15, up to 16, up to 17, up to 18, up to 19, up to 20, up to 21, up to 22, up to 23 or up to 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-8. 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-9; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-9; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20 , up to 21, up to 22, up to 23 or up to 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-10;light chain variable region and heavy chain variable region that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-11; light chain variable region and heavy chain variable region that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-12. at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-13; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-13; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most The invention further comprises light chain variable regions and heavy chain variable regions with at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-14; light chain variable region and heavy chain variable region having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-15;light chain variable region and heavy chain variable region sequences compared to the corresponding light chain and heavy chain variable region sequences of 4G9-16 at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions; light chain variable region and heavy chain variable region sequences compared to the corresponding light chain and heavy chain variable region sequences of 4G9-17 at most one, at most two, at most three, at most four at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-18; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-18; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 4G9-19; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region sequences of 4G9-19; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20 light chain variable region and heavy chain variable region having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-20;light chain variable region and heavy chain variable region sequences that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-1; light chain variable region and heavy chain variable region sequences that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-2 , at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deleted, inserted or substituted light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-3. at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 5C2-4; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, ... , up to 21, up to 22, up to 23 or up to 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions; each having up to one, up to two, up to three, up to four, up to five, up to six, up to seven, up to eight, up to nine, up to ten, up to 11, up to 12, up to 13, up to 14, up to 15, up to 16, up to 17, up to 18, up to 19, up to 20, up to 21, up to 22, up to 23 or up to 24 deletions, insertions or substitutions of light chain variable regions and heavy chain variable regions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-5;light chain variable region and heavy chain variable region sequences that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-6; light chain variable region and heavy chain variable region sequences that each have at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-7 , at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region sequences of 5C2-8; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region sequences of 5C2-8; at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 5C2-9; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23 or at most 24 deletions, insertions or substitutions in the light chain variable region and heavy chain variable region of 5C2-9; each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, light chain variable regions and heavy chain variable regions with up to 21, up to 22, up to 23, or up to 24 deletions, insertions, or substitutions; or light chain variable regions and heavy chain variable regions each with up to one, up to two, up to three, up to four, up to five, up to six, up to seven, up to eight, up to nine, up to ten, up to 11, up to 12, up to 13, up to 14, up to 15, up to 16, up to 17, up to 18, up to 19, up to 20, up to 21, up to 22, up to 23, or up to 24 deletions, insertions, or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 5C2-10.;
[0152] For example, a preferred antibody or antigen-binding fragment may comprise a light chain variable region and a heavy chain variable region, each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17 or at most 18 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-2; or a light chain variable region and a heavy chain variable region, each having at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17 or at most 18 deletions, insertions or substitutions compared to the corresponding light chain and heavy chain variable region sequences of 4G9-12.
[0153] An embodiment provides an antibody or antigen-binding fragment thereof, wherein the light chain variable region and the heavy chain variable region each independently have at least 75% identity, such as at least 85% identity, at least 90% identity or at least 95% identity with the corresponding light chain variable region and heavy chain variable region of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0154] In some embodiments, the antibody or antigen-binding fragment thereof is defined by a light chain variable region and a heavy chain variable region, each of which independently has at most one, at most two, at most three, at most four, at most five, at most six, at most seven, at most eight, at most nine, at most ten, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, or at most 18 deletions, insertions, or substitutions compared to the corresponding light chain and heavy chain variable regions of any one of antibodies 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10.
[0155] In an embodiment, the antibody or antigen-binding fragment comprises a heavy chain amino acid sequence and a light chain amino acid sequence, or an antigen-binding portion of either sequence, of the antibody 4G9-1, 4G9-2, 4G9-3, 4G9-4, 4G9-5, 4G9-6, 4G9-7, 4G9-8, 4G9-10, 5C2-1, 5C2-2, 5C2-3, 5C2-4, 5C2-5, 5C2-6, 5C2-7, 5C2-8, 5C2-9, or 5C2-10 comprising a sequence disclosed in Table 5 or Table 6. Tables 5 and 6 disclose the heavy and light chain sequences of 4G9-1 to 4G9-20 and 5C2-1 to 5C2-10 with and without a terminal lysine ("-K", heavy chain only) and with and without a signal peptide ("-SP").
[0156] Table 5: 4G9 sequence
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186] Table 6: 5C2 sequence
[0187]
[0188]
[0189]
[0190]
[0191]
[0192]
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202]
[0203] 2. Polynucleotides encoding 4G9 and 5C2 sequences
[0204] On the other hand, the present invention relates to an isolated nucleic acid molecule (e.g., a polynucleotide) encoding an antibody or antigen-binding fragment of an anti-PD1 agonist antibody disclosed herein. The present disclosure provides polynucleotides encoding antibodies or antigen-binding fragments comprising the amino acid sequences of antibodies 4G9-1 to 4G9-20 or 5C2-1 to 5C2-10 (e.g., SEQ ID NO: 1-393, Table 1-6). The polynucleotide may encode a complete antibody or its antigen-binding fragment or a light chain, a heavy chain, a combination thereof, or its CDR. In an embodiment, the polynucleotide may encode a heavy chain and / or a light chain selected from the antibodies or antigen-binding fragments shown in Tables 5 and 6 (e.g., SEQ ID NO: 214-393). In an embodiment, the polynucleotide may encode a heavy chain variable region (e.g., VH) and / or a light chain variable region (e.g., VK) selected from the heavy chain variable region shown in Tables 1-4 (e.g., SEQ ID NO: 1-20, 83-102, 143-152, and 184-193). In an embodiment, the polynucleotide may encode an antibody or antigen-binding fragment (e.g., light chain and / or heavy chain variable region / domain) comprising a CDR sequence selected from Tables 1-4 (e.g., SEQ ID NO: 21-82, 103-142, 153-183, 194-213). In an embodiment, the polynucleotide encodes the heavy chain and / or light chain variable region of 4G9-12, for example, SEQ ID NO: 12 and 94. In such embodiments, the polynucleotide optionally further encodes a heavy chain constant region and / or a light chain constant region. In an embodiment, the polynucleotide encodes the heavy chain and / or light chain variable region of 4G9-2, for example, SEQ ID NO: 2 and 84. In an embodiment, the polynucleotide encodes an antibody or antigen-binding fragment comprising a CDR sequence of 4G9-12 (e.g., SEQ ID NO: 32, 53 and 74, and / or 114, KVS and 134). In some embodiments, the polynucleotide encodes an antibody or antigen-binding fragment comprising the heavy and light chain variable regions of 4G9-12 (eg, SEQ ID NOs: 12 and 94).
[0205] Isolated polynucleotide molecules can be produced by standard techniques, including but not limited to conventional molecular cloning and chemical polynucleotide synthesis techniques. For example, polymerase chain reaction (PCR) technology can be used to obtain isolated polynucleotides encoding variant polypeptides. For example, in PCR Primer: A Laboratory Manual ,Dieffenbach and Dveksler, eds., Cold Spring Harbor Laboratory Press, 1995, describe general PCR techniques. When RNA is used as a template source, reverse transcriptase can be used to synthesize a complementary DNA (cDNA) strand. Ligase chain reaction, strand displacement amplification, self-sustained sequence replication, or polynucleotide sequence-based amplification can also be used to obtain isolated polynucleotides. See, for example, Lewis (. 1992) Genetic Engineering News 12: 1; Guatelli et al. (1990) Proc. Natl. Acad Sci. USA 87: 1874-1878; and Weiss (1991) Science 254: 1292-1293.
[0206] The isolated polynucleotide can be chemically synthesized as a single polynucleotide molecule or as a series of oligonucleotides (e.g., using phosphoramidite technology for automatic DNA synthesis in the 3' to 5' direction), for example, one or more pairs of long oligonucleotides (e.g., >100 nucleotides) containing the desired sequence can be synthesized, each pair containing a short segment of complementarity (e.g., about 15 nucleotides) so that a duplex is formed when the oligonucleotides are annealed. DNA polymerase can be used to extend the oligonucleotides so that each oligonucleotide pair produces a single double-stranded polynucleotide molecule, which can then be heated into a carrier. The isolated polynucleotide can also be obtained by mutagenesis. The polynucleotide encoding the protein can be mutated using standard techniques, including oligonucleotide-directed mutagenesis and / or site-directed mutagenesis by PER. See Short Protocols in Molecular Biology, Chapter 8, Green Publishing Associates and John Wiley & Sons, Ausubel et al., 1992.
[0207] Those of ordinary skill in the art will appreciate that the redundancy of the genetic code allows any amino acid sequence to be encoded by a large number of polynucleotides. Those of ordinary skill in the art will also appreciate that, depending on the organism in which the polynucleotide will be maintained, replicated and / or transcribed, the polynucleotide sequence encoding a specific amino acid sequence can be selected based on the codon bias of the organism.
[0208] The polynucleotide can be located in a vector (e.g., an expression vector). The polynucleotide can be introduced into a suitable host cell for expression, for example, can be extrachromosomal or inserted into a chromosome, for example, a Chinese hamster ovary (CHO) cell or a NS0 cell. Preferably, the host cell is a mammalian host cell, such as a CHO or NS0 cell, but bacteria, yeast, plants, and other types of suitable cells can also be used.
[0209] In an embodiment, the host cell can be part of a transgenic animal. Methods for making transgenic animals that produce antibodies are known in the art. See, for example, A. Jakobovits, Curt Opin Biotechnol., 6(5):5.61-6 (1995) and Brüggemann, M. et al., Arch Immunol Ther Exp (Warsz)., 63(2)101-108 (2015); Jakobovits, A. et al., "From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice." Nat Biotechnol. 25(10):113.4-43 (2007); Lonberg N. (2005) "Human antibodies from transgenic mice." animals." Nat Biotechnol. 23(9): 1117-25 and U.S. Patents Nos. 9,708,635; 9,686,970; 9,499,838; 9,445,581; 9; 388,446; 8,835,712; 8,703,485; 8,232,449; 7,795,494; and 5,939,598.
[0210] The techniques for manipulating polynucleotides, vectors, expression vectors, host cells, and transgenic animals are known in the art and need not be described in detail.
[0211] F. Pharmaceutical Compositions
[0212] Pharmaceutical compositions comprising the disclosed antibodies and antigen-binding fragments thereof are provided. Pharmaceutical compositions generally comprise one or more pharmaceutically acceptable excipients.
[0213] The pharmaceutical compositions disclosed herein are administered to a subject in a therapeutically effective amount. An "effective amount" or "therapeutically effective amount" generally refers to an amount or dosage sufficient to treat, suppress or alleviate one or more symptoms of a treated condition or otherwise provide a desired pharmacological and / or physiological effect. The exact dosage will vary according to various factors, such as subject-related variables (e.g., age, immune system health status, etc.), disease, and affected treatment.
[0214] For the disclosed antibodies and antigen-binding fragments thereof, those of ordinary skill in the art will be able to determine the appropriate dosage, taking into account the treatment background, age and general health of the recipient. The selected dosage depends on the desired therapeutic effect, route of administration and desired duration of treatment. For the disclosed antibodies and antigen-binding fragments thereof, a dosage level of 0.001 to 20 mg / kg body weight can generally be administered to mammals daily. Typically, for intravenous injection or infusion, the dosage may be lower.
[0215] In certain embodiments, the antibodies and antigen-binding fragments thereof can be administered topically, for example, by direct injection into the site to be treated. Typically, injection can result in an increased local concentration of the antibody and / or antigen-binding fragment thereof, which may be greater than that achievable by systemic administration. The antibodies and antigen-binding fragments thereof disclosed herein can be combined with a matrix as described above to help produce an increased local concentration of the polypeptide composition by reducing passive diffusion of the polypeptide out of the site to be treated.
[0216] 1. Preparations for parenteral administration
[0217] In some embodiments, compositions containing the disclosed antibodies and Fabs are administered by parenteral injection in an aqueous solution. The formulations may also be in the form of a suspension or emulsion. Generally, pharmaceutical compositions comprising a therapeutically effective amount of an antibody or Fab thereof are provided, and optionally comprising a pharmaceutically acceptable diluent, preservative, solubilizer, emulsifier, adjuvant and / or carrier. Such compositions optionally include one or more of the following: a diluent; sterile water; buffered saline of various buffer contents (e.g., Tris-HO, acetate, phosphate), pH, and ionic strength; and additives such as detergents and solubilizers (e.g., TWEEN 20 (polysorbate-20), TWEEN 80 (polysorbate-80), antioxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., thimerosal, benzyl alcohol) and filler substances (e.g., lactose, mannitol). Examples of non-aqueous solvents or vehicles include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils (such as olive oil and corn oil), gelatin, and injectable organic esters (such as ethyl oleate). The formulation may be lyophilized and redissolved / resuspended immediately before use. The formulation may be sterilized by, for example, filtration, by incorporating a sterilizing agent into the composition, by irradiating the composition, or by heating the composition.
[0218] 2. Preparations for oral administration
[0219] In some embodiments, the antibody composition is formulated for oral delivery. Oral dosage forms of antibodies can resist proteolysis and deliver a greater proportion of immunoreactive antibodies locally in the gastrointestinal tract for treating infection, or allow absorption of antibodies to treat or prevent systemic conditions (Reilly, RM et al. Clin Pharmacokinet., 32 (4): 313.M (1997); Victoria.S Jasion and Bruce: P Burnett, Nutr J.; 14: 22 (2015); and Philippart, M. et al., Drug. Res (Stuttg) 66 (03): 11.120 (2016)).
[0220] Oral solid dosage forms are generally described in Chapter 89 of Remington's Pharmaceutical Sciences, 18th Edition. 1990 (Mack Publishing Co. Easton Pa. 18042). Solid dosage forms include tablets, capsules, pills, lozenges or lozenges, cachets, pellets, powders or granules; or the material is incorporated into a particulate preparation of a polymer compound (such as polylactic acid, polyglycolic acid, etc.) or into a liposome. Such compositions can affect the physical state, stability, in vivo release rate and in vivo clearance rate of the antibody or antigen-binding fragment. See, for example, Remington's Pharmaceutical Sciences, 18th Edition. (1990, Mack Publishing. Co., Easton, Pa. 18042) pages 1435-1712, which is incorporated herein by reference.
[0221] The composition can be prepared in liquid form, or can be in dry powder (e.g., lyophilized) form. Liposome or protein-like encapsulation can be used to prepare the composition. Liposome encapsulation can be used and liposomes can be derived with various polymers (e.g., U.S. Patent No. 5,013,556). See also Marshall, K. In: Modern Pharmaceutics, GS Banker and CT Rhodes, Chapter 10, 1979. Generally speaking, the preparation will include an antibody or antigen-binding fragment (or its chemically modified form) and an inert component that protects the antibody or antigen-binding fragment in the gastric environment and releases the bioactive substance in the intestine.
[0222] Antibodies and antigen-binding fragments thereof can be chemically modified to allow for effective oral delivery of the derivatives. Typically, the chemical modification contemplated is the attachment of at least one moiety to the component molecule itself, wherein the moiety allows uptake from the stomach or intestine into the bloodstream, or directly into the intestinal mucosa. It is also desirable to improve the overall stability of the component and increase the in vivo circulation time. PEGylation is an exemplary chemical modification for pharmaceutical use. Other moieties that can be used include propylene glycol, copolymers of ethylene glycol and propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, polyproline, poly-1,3-dioxolane, and poly-1,3,6-trioxocane [see, e.g., Abuchowski and Davis. (1981) "Soluble Polymer-Enzyme Adducts," in Enzymes as Drugs. Hocenberg and Roberts, OS. (Wiley-Interscience: New York, NY) pp. 367-383; and Newmark et al. (1982) J. App, Biochem. 4: 185-189.
[0223] Another embodiment provides liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions and syrups, which may contain other components including inert diluents; adjuvants such as wetting agents, emulsifying agents and suspending agents; and sweeteners, flavoring agents and perfuming agents.
[0224] For oral formulations, the release site can be the stomach, small intestine (duodenum, jejunum or ileum) or large intestine. In some embodiments, by protecting the medicament (or derivative) or by releasing the medicament (or derivative) outside the gastric environment (such as in the intestine), the release will avoid the harmful effects of the gastric environment. In order to ensure complete gastric resistance, it is required to be impermeable to at least pH 5.0. The example of the more common inert ingredient used as enteric coating is cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (HPMCP), HPMCP 50, HPMCP-55, polyvinyl acetate-phthalate (PVAP), Eudragit L30D TM 、Aquateric TM Cellulose acetate phthalate (CAP), EudragitL TM 、Eudragit S TM and Shellac TM These coatings can be used as hybrid films.
[0225] 3. Controlled delivery polymer matrix
[0226] The antibodies and AFs thereof disclosed herein can also be administered in the form of controlled release formulations. The antibodies and AFs thereof can be incorporated into an inert matrix that allows release by diffusion or leaching mechanisms, such as gums. Slowly degradable matrices can also be incorporated into the formulation. Another form of controlled release is based on the Oros therapeutic system (Alza Corp.), which is to encapsulate the antibody or AFs thereof in a semipermeable membrane that allows water to enter and push the drug out through a single small opening due to osmosis.
[0227] Controlled release polymer devices can be made for long-term systemic release after implantation of polymer devices (rods, cylinders, membrane discs) or injection (microparticles). The matrix can be in the form of microparticles, such as microspheres, wherein the medicament is dispersed in a solid polymer matrix or microcapsules, wherein the core is a material different from the polymer shell, and the peptide is dispersed or suspended in the core, which can be liquid or solid in nature. Unless specifically defined herein, microparticles, microspheres and microcapsules are used interchangeably. Alternatively, polymers can be cast into nanometers to thin sheets or films within the centimeter range, powders produced by grinding or other standard techniques, or gels such as hydrogels.
[0228] Non-biodegradable or biodegradable matrices can be used to deliver agonist anti-PD-1 antibodies, antigen-binding fragments, or nucleic acids encoding agonist anti-PD-1 antibodies or antigen-binding fragments, but in some embodiments a biodegradable matrix is required. These can be natural or synthetic polymers, but in some embodiments, synthetic polymers are required due to better degradation and release curve characterization. The polymer is selected based on the time of release required. In some cases, linear release may be most useful, but in other cases, pulsed release or "mass release" may provide more effective results. The polymer can be at the bottom of the hydrogel (typically absorbing up to about 90% by weight of water) and can be optionally cross-linked with multivalent ions or polymers.
[0229] The matrix can be formed by solvent evaporation, spray drying, solvent extraction, and other methods known to those skilled in the art. Bioerodible microspheres can be prepared using any method developed for preparing microspheres for drug delivery, such as by Mathiowitz and Langer, J. Controlled Release, 5: 13.22 (1987); Mathiowitz et al., Reclaim Polymers, 6: 275-283 (1987); and Mathiowitz et al., J. Appl. Polymer Sci., 35: 755-774 (1988).
[0230] The device can be formulated for local release to treat the area of implantation or injection (usually the dose delivered will be much less than the dose for whole body treatment) or systemic delivery. These can be implanted or injected subcutaneously into muscle, fat, or swallowed.
[0231] G. Manufacturing method
[0232] 1. Methods for preparing antibodies
[0233] The disclosed antibodies can be produced in cell culture, phage or various animals, including but not limited to cattle, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees and apes. In embodiments, various animals can be transgenic animals that are genetically engineered to produce human or humanized antibodies. In embodiments, the antibodies are mammalian antibodies. Phage technology can be used to separate initial antibodies or generate variants with altered specificity or affinity characteristics. This technology is conventional and well known in the art. In embodiments, antibodies are produced by recombinant methods known in the art. For example, recombinant antibodies can be produced by transfecting host cells with vectors containing DNA sequences encoding antibodies. One or more vectors can be used to transfect DNA sequences expressing at least one VL and one VH region in a host cell. Exemplary descriptions of recombinant methods for antibody generation and production include Delves, Antibody Production: Essential Techniques (Wiley, 1997).; Shephard et al., Monoclonal Antibodies (Oxford University Press, 2000); Goding, Monoclonal Antibodies: Principles And Practice (Academic Press, 1993); Current Protocols In Immunology (John Wiley & Sons, latest edition).
[0234] The disclosed antibodies and antigen-binding fragments can be modified by recombinant means to increase the greater efficacy of the antibodies in mediating the desired function. In other words, the antibodies and antigen-binding fragments can be modified by substitution using recombinant means. Typically, the substitution will be a conservative substitution. For example, at least one amino acid in the constant region of an antibody or antigen-binding fragment can be replaced by a different residue. See, for example, U.S. Patent No. 5,624,821, U.S. Patent No. 6,194,551, Application No. WO 9958572; Angal et al., Mol Immunol. 30: 105-08 (1993). Amino acid modification includes deletion, addition and substitution of amino acids. In some cases, such changes are made to reduce undesirable activities, such as complement-dependent cytotoxicity. Typically, antibodies are labeled by covalently or non-covalently linking a substance that provides a detectable signal. Various labeling and conjugation techniques are known and widely reported in scientific and patent literature. These antibodies can be screened for binding to proteins or polypeptides. See, e.g., Antibody Engineering: A Practical Approach (Oxford University Press, 1996).
[0235] For example, suitable antibodies with desired biological activity can be identified using in vitro assays, including but not limited to proliferation, migration, adhesion, soft agar growth, angiogenesis, cell-to-cell communication, apoptosis, transport, signal transduction, and in vivo assays such as inhibition of tumor growth. The antibodies provided herein can also be used for diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for their ability to bind to specific antigens without inhibiting receptor binding or biological activity of the antigen. As neutralizing antibodies, antibodies can be used in competitive binding assays.
[0236] Another embodiment provides a monoclonal antibody obtained from a substantially homologous antibody population, i.e., a single antibody. The population is identical except for naturally occurring mutations that may be present in a small portion of the antibody molecule. Monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and / or light chains is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity.
[0237] Any method for producing monoclonal antibodies can be used to prepare monoclonal antibodies. In the hybridoma method, mice or other suitable host animals are usually immunized with an immunizing agent to induce lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, lymphocytes can be immunized in vitro.
[0238] The disclosed antibodies can also be prepared by recombinant DNA methods. The DNA encoding the disclosed antibodies can be easily isolated and sequenced using conventional methods (e.g., by using oligonucleotide probes that can specifically bind to the genes encoding the heavy and light chains of the miniantibodies). Phage display technology can also be used to generate and screen libraries of antibodies or active antibody fragments (e.g., antigen binding fragments).
[0239] Methods for preparing antibodies using protein chemistry are also known in the art. One method for producing proteins comprising antibodies is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, currently available laboratory equipment can be used to chemically synthesize peptides or polypeptides using Fmoc (9-fluorenylmethoxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). It can be easily understood by those skilled in the art that, for example, peptides or polypeptides corresponding to antibodies can be synthesized by standard chemical reactions. For example, peptides or polypeptides can be synthesized, and other fragments of antibodies can be synthesized without cutting from their synthetic resins, and then cut from the resins to expose the functionally blocked terminal groups on other fragments. Through peptide condensation reactions, the two fragments can be covalently linked via peptide bonds at their carboxyl and amino termini, respectively, to form antibodies or their fragments. Alternatively, as described above, peptides or polypeptides are synthesized independently in vivo. Once separated, these independent peptides or polypeptides can be connected via similar peptide condensation reactions to form antibodies or their antigen-binding fragments.
[0240] For example, enzymatic ligation of cloned or synthesized peptide segments allows relatively short peptide fragments to be connected to produce larger peptide fragments, polypeptides or entire protein domains. Alternatively, natural chemical ligation of synthetic peptides can be used to synthesize large peptides or polypeptides from shorter peptide fragments. The method consists of a two-step chemical reaction. The first step is a chemoselective reaction of an unprotected synthetic peptide-α-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to obtain a thioester-connected intermediate as an initial covalent product. Without changing the reaction conditions, the intermediate undergoes a spontaneous, rapid intramolecular reaction to form a natural peptide bond at the connection site.
[0241] H. How to use
[0242] The disclosed antibodies and antigen-binding fragments thereof can be used to modulate the immune response of a subject in need thereof. One embodiment provides a method of activating immune cells (e.g., T cells) expressing PD-1 to proliferate or enhance the biological activity of immune cells expressing PD-1 by administering the disclosed antibodies and antigen-binding fragments thereof (optionally including a second therapeutic agent).
[0243] 1. Stimulation of immune response
[0244] a. Treatment strategies
[0245] A method for inducing or enhancing an immune response in a subject is provided. Generally, the method comprises administering to the subject a therapeutically effective amount of one or more disclosed antibodies and antigen-binding fragments thereof, to immunospecifically bind to PD-1, and to induce, promote or enhance stimulation or activation signals through PD-1 to activate immune cells. The immune response may be, for example, inducing, promoting or enhancing T cell activation, immune cell secretion of cytokines, T cell proliferation. The disclosed antibodies or antigen-binding fragments thereof may be administered to a subject in need in a therapeutically effective amount to overcome T cell exhaustion and / or T cell energy. By measuring T cell function using known techniques, it can be determined that I cell exhaustion or T cell anergy is overcome.
[0246] The method can be used in vivo or ex vivo to induce, promote or enhance a stimulatory immune response.
[0247] In some embodiments, the antibody or its antigen binding fragment is directly administered to the subject. A nucleic acid encoding the antibody or its antigen binding fragment can also be administered to the subject. Preferably, the nucleic acid can be expressed once administered to produce an antibody or antigen binding fragment that binds to PD-1. In some embodiments, the antibody or its antigen binding fragment is contacted with a cell (e.g., an immune cell) in vitro, and the treated cell is administered to the subject (e.g., adoptive transfer). The antibody or its antigen binding fragment can make a stronger immune response possible. The disclosed composition can be used to stimulate or enhance an immune response involving T cells, thereby causing an activation signal through PD-1 on immune cells.
[0248] 2. Subjects to be treated
[0249] a. Cancer treatment
[0250] The disclosed antibodies and compositions and methods thereof can be used to treat cancer. Typically, the medicament is used to stimulate or enhance the subject's immune response to cancer by administering a certain amount of the disclosed antibody or its antigen-binding fragment to the subject, and the disclosed antibody or its antigen-binding fragment induces, promotes or enhances activation signals through PD-1. The method can alleviate one or more symptoms of cancer. The method can be used to reduce or inhibit tumor growth or cause tumor regression. For example, as disclosed and illustrated herein, the antibody or antigen-binding fragment of the present disclosure has anti-tumor activity and can also induce central memory T cells (Tcm) and / or inhibit T cell exhaustion.
[0251] Immune cells activated by the disclosed antibodies or fragments thereof can kill cancer cells and reduce the tumor load of the subject. Tumors can be benign or malignant, and if malignant, at any stage of disease progression. In other embodiments, cancer is associated with specific cancer antigens (e.g., pan-cancer antigens (KS1 / 4), ovarian cancer antigens (CA125), prostate-specific antigens (PSA), carcinoembryonic antigens (CEA), CD19, CD20, HER2 / neu, etc.).
[0252] The methods and antibody compositions disclosed herein can be used to treat or prevent a variety of cancers or other abnormal proliferative diseases, including, but not limited to, cancers including bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, and skin cancer; including squamous cell carcinoma; lymphoid hematopoietic system tumors including leukemias, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burkitt's lymphoma; myeloid hematopoietic tumors, including acute and chronic Myeloid and promyelocytic leukemias; mesenchymal tumors, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, teratoma, neuroblastoma, and glioma; central and peripheral nervous system tumors, including astrocytoma, neuroblastoma, glioma, and schwannoma; mesenchymal tumors, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, follicular thyroid carcinoma, and teratoma.
[0253] Cancers caused by abnormal apoptosis can also be treated by the disclosed methods and compositions. Such cancers may include, but are not limited to, follicular lymphoma, p53 mutant cancer, hormone-dependent tumors of the breast, prostate, and ovary, and precancerous lesions, such as familial adenomatous polyposis and myelodysplastic syndrome. In a specific embodiment, malignant tumors or abnormal changes in proliferation (such as metaplasia and dysplasia) or hyperproliferative disorders in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus may be treated or prevented by the methods and compositions. In other specific embodiments, sarcomas, melanomas, or leukemias are treated or prevented by the methods and compositions.
[0254] Specific cancers and related conditions that may be treated or prevented by the methods and compositions disclosed herein include, but are not limited to, leukemias, including, but not limited to, acute leukemias, acute lymphocytic leukemias, acute myeloid leukemias such as myeloblastic leukemia, promyelocytic leukemia, myelomonocytic leukemia, monocytic leukemia, erythroleukemia, and myelodysplastic syndromes, chronic leukemias, such as, but not limited to, chronic myeloid (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, such as, but not limited to, Hodgkin's disease or non-Hodgkin's disease. Stinkin's disease lymphoma (e.g., diffuse anaplastic lymphoma kinase (ALK) negative, large B-cell lymphoma (DLBCL); diffuse anaplastic lymphoma kinase (ALX) positive, large B-cell lymphoma (DLBCL); anaplastic lymphoma kinase (ALK) positive, ALK+ anaplastic large cell lymphoma (ALCL), acute myeloid lymphoma (AML)); multiple myeloma, such as but not limited to smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia ( benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, such as, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft tissue sarcoma, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurothecoma, rhabdomyosarcoma, synovial sarcoma; brain tumors, including, but not limited to, gliomas, astrocytomas, brain stem gliomas, ependymomas, oligodendrogliomas, non-glial tumors, acoustic neuroma, craniopharyngioma, neuroblastoma ovarian cancer, including, but not limited to, pheochromocytoma and adrenocortical carcinoma; thyroid cancer, such as, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vasodilator peptide tumor, somatostatin secreting tumor, and carcinoid or islet cell tumor; pituitary cancer, including, but not limited to, Cushing's disease, prolactin-secreting tumors, acromegaly, and diabetes insipidus; eye cancers, including but not limited to ocular melanomas, such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancers, including but not limited to squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancers, including but not limited to squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers, including but not limited to squamous cell carcinoma and adenocarcinoma; uterine cancers, including but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancers, including but not limited to epithelial ovarian cancer, borderline tumors, germ cell tumors, and stromal tumors; esophageal cancers, including but not limited to Not limited to squamous carcinoma, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma and oat cell (small cell) carcinoma; gastric cancer, including but not limited to adenocarcinoma, fungus (polypoid) ulcer carcinoma, superficial spreading carcinoma, diffuse spreading carcinoma, malignant lymphoma, liposarcoma, fibrosarcoma and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including but not limited to hepatocellular carcinoma and hepatoblastoma; gallbladder cancer, including but not limited to adenocarcinoma; bile duct cancer, including but not limited to papillary, nodular and diffuse; lung cancer, including but not limited to non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large cell carcinoma and small cell lung cancer;Testicular cancer, including but not limited to reproductive tumors seminoma, anaplastic, classical (typical) spermatocytoma, non-seminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk sac tumor); prostate cancer, including but not limited to adenocarcinoma, leiomyosarcoma and rhabdomyosarcoma; penile cancer; oral cancer, including but not limited to squamous cell carcinoma; basal carcinoma; salivary gland cancer, including but not limited to adenocarcinoma, mucoepidermoid carcinoma and adenoid cystic carcinoma; pharyngeal cancer, including but not limited to basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, small nevus malignant melanoma, acral lentiginous melanoma; kidney cancer, including but not limited to renal cell carcinoma, adenocarcinoma, adrenal tumor, fibrosarcoma, transitional cell carcinoma (renal pelvis and / or uterus); Wilms' tumor; bladder cancer, including but not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, carcinosarcoma. In addition, cancers include sarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial cancer, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinoma (for reviews of these diseases, see Fishman et al., 1985, Medicine, 2nd ed., JB Lippincott Co., Philadelphia and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment and Recovery, Viking Penguin, Penguin Books USA, Inc., United States of America). In a specific example, an agonist anti-PD-1 antibody or antigen-binding fragment (e.g., an antibody having the heavy and light chain CDRs of 4G9-12) is used to treat non-small cell lung cancer in a patient in need thereof. For example, the present invention relates to a method for treating non-small cell lung cancer, comprising administering a therapeutically effective amount of an agonist anti-PD-1 antibody or antigen-binding fragment (e.g., an antibody having the heavy chain and light chain CDRs of 4G9-12) to a subject in need thereof. ;
[0255] Agonist anti-PD-1 antibodies and antigen-binding fragments disclosed herein can be used to treat cancers that are resistant or resistant to checkpoint inhibition therapy. Resistance to checkpoint inhibition therapy can be primary resistance (e.g., cancer is refractory to the first and subsequent treatments with checkpoint inhibition therapy), or can be secondary resistance (e.g., cancer responds to the first or initial treatment, but is refractory to subsequent treatments with checkpoint inhibition therapy). For example, resistance to checkpoint inhibition therapy can be generated by downregulating or lacking the expression of PD-L1 in tumors (e.g., PD-L1 negative cancers).
[0256] In some preferred embodiments, the agonist anti-PD-1 antibodies and antigen-binding fragments disclosed herein can be used to treat cancer subjects with secondary resistance to checkpoint inhibition therapy (such as PD-1 checkpoint inhibition therapy). Therefore, the present disclosure relates to a method of treating a cancer with secondary resistance to checkpoint inhibition therapy (e.g., PD-1 checkpoint inhibition therapy), comprising administering to a subject in need thereof a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment disclosed herein.
[0257] In some preferred embodiments, the agonist anti-PD-1 antibodies and antigen-binding fragments disclosed herein can be used to treat cancer subjects with primary resistance to PD-1 checkpoint inhibition. Therefore, the present disclosure relates to a method of treating a cancer with primary resistance to checkpoint inhibition therapy (e.g., PD-1 checkpoint inhibition therapy), comprising administering to a subject in need thereof a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment disclosed herein.
[0258] In some preferred embodiments, the agonist anti-PD-1 antibodies and antigen-binding fragments disclosed herein can be used to treat subjects with PD-L1 negative tumors (e.g., cancers with downregulated PD-L1). Therefore, the present disclosure relates to a method of treating a cancer that is PD-L1 negative (e.g., a cancer with downregulated PD-L1), comprising administering to a subject in need thereof a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment disclosed herein.
[0259] b. Treatment of infection
[0260] The disclosed antibody compositions and methods can be used to treat infections and infectious diseases. The medicament is used to stimulate or enhance the subject's immune response to infection by administering to the subject a certain amount of one or more disclosed antibodies or antigen-binding fragments thereof, which send activation or stimulation signals through PD-1. The method can alleviate one or more symptoms of infection.
[0261] Infection or disease can be caused by bacteria, viruses, protozoa, helminths or other microbial pathogens that enter cells and are attacked by cytotoxic T lymphocytes.
[0262] Infection or disease can be acute or chronic. Acute infection is usually an infection of shorter duration. During acute microbial infection, immune cells begin to express immunomodulatory receptors. Therefore, in some embodiments, the method includes increasing the immune stimulation response to acute infection.
[0263] The infection may be caused by, for example, but not limited to, Candida albicans, Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae, Neisseria meningitidis, Staphylococcus aureus; Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, or Mycobacteria.
[0264] In some embodiments, the disclosed antibody compositions are used to treat chronic infections, e.g., infections in which T cell exhaustion has occurred, resulting in the infection persisting in the host for a longer period of time.
[0265] Exemplary infections to be treated include chronic infections caused by hepatitis viruses, human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), herpes viruses, Epstein-Barr virus, or human papillomavirus.
[0266] Because viral infections are primarily cleared by T cells, an increase in T cell activity would be therapeutically useful in cases where faster or more thorough clearance of infectious viral agents is beneficial to an animal or human subject. Thus, the disclosed compositions can be used to treat local or systemic viral infections, including but not limited to immunodeficiency (e.g., HIV, papilloma (e.g., HPV), herpes (e.g., HSV), encephalitis, influenza (e.g., human influenza virus A) and the common cold (e.g., human rhinovirus) and other viral infections caused by, for example, HTLV, hepatitis viruses, respiratory syncytial viruses, vaccinia viruses, rabies viruses, and SARS-CoV2 viruses. These molecules can be topically administered to treat viral skin diseases, such as herpes lesions, herpes zoster, or genital warts. These molecules can also be systemically administered to treat systemic viral diseases, including but not limited to AIDS, influenza, the common cold, covid-19, or encephalitis.
[0267] Representative infections that can be treated include, but are not limited to, infections caused by microorganisms, including, but are not limited to, Actinomycetes, Anabaena, Bacillus, Bacteroides, Bdellovibrio, Bordetella, Borrelia, Campylobacter, Caulobacter, Chlamydia, Green sulfur bacteria, Chromobacteria, Clostridium, Corynebacterium, Cytophaga, Deinococcus, Escherichia, Francisella, Halobacterium; Helicobacter, Haemophilus, Haemophilus influenzae type II -(HIB), Hyphomicrobium, Legionella, Leptospirosis, Listeria, Meningococcus A, B and C, Methanobacterium, Micrococcus, Mycobacterium, Mycoplasma, Myxococcus, Neisseria, Nitrobacter, Oscillatoria, Prochlorococcus, Proteus, Pseudomonas, Rhodospirillum, Rickettsia, Salmonella, Shigella, Spirochete, Spirochete, Staphylococcus, Streptococcus, Streptomyces, Sulfolobus, Pyroplasma, Thiobacillus and Treponema, Vibrio, Yersinia, Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi typhi), Mycoplasma pneumoniae, Chlamydialpsittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis, and Schistosoma mansoni.
[0268] Other microorganisms that can be treated using the disclosed compositions and methods include bacteria, such as Klebsiella, Serratia, Pasteurella; pathogens associated with cholera, tetanus, botulism, anthrax, plague, and Lyme disease; or fungal or parasitic pathogens, such as Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus, Aspergillus (fumigatus, niger, etc.), Mucorales (Mucor, Absidia, Rhizopus), Sporothrix (Schenckia), Blastomyces (Blastomyces dermatitidis), Paracoccidioides (Paracoccidioides brasiliensis), Coccidioides (C. immitis), and Histoplasma (Histoplasma capsulatum), Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba (Acanthamoeba spp.), and other fungal pathogens. sp.), Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii, etc.), Sporothrix, Blastomyces, Paracoccidioides, Coccidioides, Histoplasma, Entamoeba histolytica, Balanadium, Naegleria, Acanthamoeba, Giardia, Cryptosporidium, Pneumocystis, Plasmodium, Babesia or Trypanosoma, etc.
[0269] c. Combination therapy for enhancing immune response
[0270] The disclosed antibodies and antigen-binding fragments thereof and compositions thereof can be administered to a subject in need alone or in combination with one or more additional therapeutic agents. In some embodiments, the antibody and antigen-binding fragment thereof and the additional therapeutic agent are administered separately but simultaneously. The antibody and antigen-binding fragment thereof and the additional therapeutic agent can also be administered as part of the same composition. In other embodiments, the antibody and antigen-binding fragment thereof and the second therapeutic agent are administered separately at different times but as part of the same treatment regimen. The additional therapeutic agent can be administered before, after, or alternately with the administration of the disclosed antibody and antigen-binding fragment thereof.
[0271] The first therapeutic agent may be administered to the subject 1, 2, 3, 4, 5, 6, or more hours, or 1, 2, 3, 4, 5, 6, 7, or more days prior to administration of the second therapeutic agent. In embodiments, the first therapeutic agent may be administered to the subject 1, 2, 3, 4, 5, 6, 7, or more days prior to administration of the second therapeutic agent. - One or more doses of the first agent are administered to the subject on day 7, 14, 21, 28, 35 or 48. Antibodies and antigen-binding fragments thereof can be the first or second therapeutic agent.
[0272] The antibodies and antigen-binding fragments thereof and the additional therapeutic agent can be administered as part of a treatment regimen. For example, if the first therapeutic agent can be administered to the subject every four days, the second therapeutic agent can be administered on the first, second, third, or fourth day, or a combination thereof. The first therapeutic agent or the second therapeutic agent can be administered repeatedly throughout the treatment regimen.
[0273] Exemplary additional therapeutic agents include, but are not limited to, cytokines (e.g., IL-2, IL-12), chemotherapeutic agents, radionuclides, other immunotherapeutic agents, enzymes, antibiotics, antiviral agents (particularly protease inhibitors alone or in combination with nucleosides for the treatment of HIV or hepatitis B or C), antiparasitic agents, growth factors, growth inhibitory agents, hormones, hormone antagonists, antibodies and biologically active fragments thereof (including humanized, single chain and chimeric antibodies), antigens and vaccine formulations (including adjuvants), peptide drugs, anti-inflammatory agents, ligands that bind to Toll-like receptors (including but not limited to CpG oligonucleotides) to activate the innate immune system, molecules that mobilize and optimize the adaptive immune system (e.g., bispecific T cell engagers), other molecules that activate or upregulate the action of cytotoxic T lymphocytes, natural killer cells, and helper T cells, and other molecules that inactivate or downregulate suppressive or regulatory T cells.
[0274] Additional therapeutic agents can be selected based on the condition, disorder or disease to be treated. For example, the antibodies or antigen-binding fragments disclosed herein can be co-administered with one or more additional agents that act to enhance or promote an immune response or to reduce or inhibit an immune response. The selection of additional therapeutic agents other than the antibodies or antigen-binding fragments disclosed herein is a routine matter for those of ordinary skill in the art who benefit from the present disclosure.
[0275] Suitable additional therapeutic agents for use with anti-PD-1 agonist antibodies or antigen-binding fragments described herein include cell therapy. Suitable cell therapy may include, for example, dendritic cells, B cells, T cells (e.g., αβT cells, CD3+T cells, CD4+T cells, CD8+T cells, γδT cells, etc.), macrophages, NK cells, NKT cells, and combinations thereof. Suitable cell therapy includes, but is not limited to, stem cell therapy, T cell therapy (e.g., tumor infiltrating lymphocytes (TIL)) or engineered cell therapy (e.g., chimeric antigen receptor (CAR) therapy, engineered TCR therapy). In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and cell therapy can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of PD-1 agonist antibodies or antigen-binding fragments as disclosed herein and cell therapy to a subject in need. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and T cell therapy can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen binding fragment as disclosed herein and a T cell therapy to a subject in need. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen binding fragments disclosed herein and tumor infiltrating lymphocytes (TIL) can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen binding fragment as disclosed herein and tumor infiltrating lymphocytes (TIL) to a subject in need. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen binding fragments disclosed herein and engineered cell therapy (e.g., engineered TCR therapy, chimeric antigen receptor (CAR) therapy, or a combination thereof) can be used to treat subjects with cancer. Accordingly, the present disclosure relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and an engineered cell therapy (e.g., an engineered TCR therapy, a chimeric antigen receptor (CAR) therapy, or a combination thereof).
[0276] An example of a suitable engineered cell therapy is chimeric antigen receptor therapy. Chimeric antigen receptor therapy can be CAR-T cells (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel), CAR-NK cells, CAR-macrophages, and combinations thereof. In some aspects, the disclosure relates to administering agonist anti-PD-1 antibodies to subjects in need together with CAR-T cells. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and antigen binding fragments disclosed herein with CAR-T cells can be used to treat cancer in subjects in need. Accordingly, the present disclosure relates to a method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a combination of agonist anti-PD-1 antibodies and antigen-binding fragments as disclosed herein and CAR-T cells.
[0277] Another example of a suitable engineered cell therapy is an engineered T cell receptor therapy. Engineered T cell receptor therapy may include engineered TCRs, TCR subunits, TCR fragments, and combinations thereof. Suitable engineered T cell receptor therapies include, but are not limited to, engineered TCR T cells (TCR-T cells), engineered TCR natural killer cells (TCR-NK), engineered TCR macrophages (TCR-macrophages), and combinations thereof. For example, an agonist anti-PD-1 antibody or an antigen-binding fragment thereof may be combined with a CD8 T cell expressing an engineered TCR (e.g., transduced with it). + As another example, an agonist anti-PD-1 antibody or antigen-binding fragment thereof can be combined with a CD4 T cell expressing an engineered TCR (e.g., transduced with it). + T cell combination. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and antigen binding fragments disclosed herein and engineered TCR T cells (TCR-T cells) can be used to treat cancer in subjects in need. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of an agonist anti-PD-1 antibody or antigen binding fragment as disclosed herein and an engineered TCR T cell (TCR-T cell) to a subject in need.
[0278] When an agonist anti-PD-1 antibody or antigen-binding fragment as disclosed herein is combined with a cell therapy, the two therapies can be administered to a subject in need thereof substantially simultaneously (e.g., simultaneously), or the cell therapy can be administered before or after the PD-1 antibody or antigen-binding fragment thereof. Although the administration time of each therapeutic agent can be different, generally their administration is such that their respective pharmacological activities in the subject overlap.
[0279] Engineered TCRs or chimeric antigen receptors can be designed to bind to any antigen. For example, a TCR or chimeric antigen receptor can specifically bind to one of the following antigens: CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-β, SSEA-4, CD20, folate receptor α, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostate enzymes, PAP, ELF2M, Ephrin B2, FAP, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor β, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, legumin, HPV E6, E7, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, fibronectin EDB (EDB-FN), 5T4 carcinoembryonic antigen, and IGLL1.
[0280] Other therapeutic agents suitable for combination with anti-PD-1 agonist antibodies include immunomodulators, which target and change the patient's immune response, such as providing an enhanced immune effector response to a tumor. Examples of suitable immunomodulators include immunostimulatory molecules, such as cytokines (e.g., IL-2, IL-12, etc.), adjuvants, T cell conjugates, and immunostimulatory antibodies (e.g., anti-CD3) and agents that block inhibitory immune pathways, such as immune checkpoint inhibitors (e.g., antibodies that bind to immune checkpoint proteins). Immune checkpoint inhibitors include antibodies and antigen binding fragments that bind to immune checkpoint proteins, such as PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), CTLA-4 (CD152) that binds to B7-1 (CD80) and B7-2 (CD86), LAGs that bind to galectin 3, LSECtin, and FGL1 3 (CD223); TIM3 (HAVCR2) that binds to ligands Ceacam1 and galectin 9; TIGIT (VSTM3, WUCAM) that binds to CD112 and CD155; BTLA (CD272) that binds to HVEM (TNFRSF14); B7-H3 (CD276), B7-H4 (VTCN1), VISTA (B7-H5), KIR, CD44 (2B4), CD160 (BY55) that bind to HVEM; CD134 (TNRFSR4, OX40) that binds to CD252 (OX-40L), etc. Many therapeutic agents such as antibodies that bind to immune checkpoint proteins and inhibit their immunosuppressive activity have been developed as anti-tumor agents. Several such agents are now commercially available for cancer treatment, including the anti-PD1 antibodies pembrolizumab, dostarlimab, cemiplimab-rwlc, nivolumab, camrelizumab, tislelizumab, toripalimab, and sintilimab; the anti-PD-L1 antibodies avelumab, durvalumab, and atezolizumab; the anti-CTLA-4 antibody ipilimumab; and the anti-LAG-3 antibody relatlimab. In some aspects, the present disclosure relates to a combination of an agonist anti-PD-1 antibody and an anti-CTLA4 antibody (e.g., ipilimumab). In some aspects, the disclosure relates to a combination of an agonist anti-PD-1 antibody and an anti-LAG-3 antibody (eg, relalizumab).In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and immunomodulators can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and an immunomodulator to a subject in need thereof. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and anti-CTLA4 antibodies or antigen-binding fragments thereof can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and an anti-CTLA4 antibody or antigen-binding fragment thereof to a subject in need thereof. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and anti-LAG-3 antibodies or antigen-binding fragments thereof can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and an anti-LAG-3 antibody or antigen-binding fragment thereof.
[0281] In a preferred embodiment, the agonist anti-PD1 antibody or antigen-binding fragment is administered with a checkpoint inhibitor that does not bind to PD-L1, PD-L2 and / or PD-1. For example, an agonist anti-PD1 antibody or antigen-binding fragment is administered with an antibody that binds any of the following: CTLA-4 (CD152) that binds B7-1 (CD80) and B7-2 (CD86), LAG 3 (CD223) that binds galectin 3, LSECtin, and FGL1; TIM3 (HAVCR2) that binds the ligands Ceacam1 and galectin 9; TIGIT (VSTM3, WUCAM) that binds CD112 and CD155; BTLA (CD272) that binds HVEM (TNFRSF14), B7-H3 (CD276) that binds HVEM, B7-H4 (VTCN1), VISTA (B7-H5), KIR, CD44 (2B4), CD160 (BY55); CD134 (TNRFSR4, OX40) that binds CD252 (OX-40L). In a more specific example, the checkpoint inhibitor is an anti-CTLA-4 antibody such as ipilimumab and / or an anti-LAG-3 antibody such as relalizumab. In some preferred embodiments, the combination of agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and checkpoint inhibitors (e.g., checkpoint inhibitors that do not inhibit the interaction of PD-1 with PD-L1 or PD-L2) can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and a checkpoint inhibitor (e.g., a checkpoint inhibitor that does not inhibit the interaction of PD-1 with PD-L1 or PD-L2) to a subject in need.
[0282] In a specific embodiment, the antibody and its antigen-binding fragment can be co-administered with a PD-1 antagonist, which refers to a molecule that inhibits the inhibition of PD-L1 on PD-1. In some embodiments, the PD-1 antagonist directly binds to the PD-1 receptor without triggering inhibitory signal transduction, and also binds to the ligand of the PD-1 receptor to reduce or inhibit the ligand-triggered signal transduction through the PD-1 receptor. By reducing the number and / or amount of ligands that bind to the PD-1 receptor and trigger inhibitory signal transduction, fewer cells are weakened by the negative signals transmitted by the PD-1 signal transduction, and a stronger immune response can be achieved.
[0283] It is believed that PD-1 signaling is driven by binding to PD-1 ligands (such as 87-H1 or Er-DC), which are in close proximity to peptide antigens presented by the major histocompatibility complex (MHC) (see, e.g., Freeman, Proc. Nail. Acad. Sci; KA, 105: 10275-10276 (2008)). Therefore, proteins, antibodies or small molecules that prevent PD-1 and TCR from being co-attached on the cell membrane are also useful PD-1 antagonists.
[0284] In some embodiments, the PD-1 receptor antagonist is a small molecule antagonist or antibody that reduces or interferes with PD-1 receptor signal transduction by binding to a ligand of PD-1 or PD-1 itself, especially in cases where co-ligation of PD-1 with the TCR does not follow such binding, thereby not triggering inhibitory signal transduction through the PD-1 receptor. Other PD-1 antagonists contemplated by the methods of the present invention include antibodies that bind to PD-1 or a ligand of PD-1, as well as other antibodies.
[0285] Suitable anti-PD-1 antibodies include, but are not limited to, those described in U.S. Pat. Nos. 7,332,582, 7,488,802, 7,521,051, 7,524,498, 7,563,869, 7,981,416, 8,088,905, 8,287,856, 8,580,247, 8,728,474, 8,779,105, 9,067,999, 9,073,994, 9,084,776, 9,205,148, 9,358,289, 9,387,247, 9,492,539, 9,492,540, all of which are incorporated by reference in their entirety. See also Berger et al., Clin, Cancer Res., 14:30443051 (2008).
[0286] Exemplary anti-PD-L1 antibodies include, but are not limited to, those described in U.S. Pat. Nos. 8,383,796, 9,102,725, 9,273,135, 9,393,301, and 9,580,507, all of which are specifically incorporated herein by reference in their entireties.
[0287] Exemplary anti-PD-L2 antibodies include, but are not limited to, those described in U.S. Pat. Nos. 7,411,051, 7,052,694, 7,390,888, 8188238, and 9255147, all of which are specifically incorporated herein by reference in their entirety.
[0288] Other examples of suitable immunomodulators for use in combination with agonist anti-PD-1 antibodies or antigen-binding fragments described herein include T cell engagement therapy (e.g., T cell engagers). T cell engagers are agents that direct T cell cytotoxic activity to target tumors. Suitable T cell engagers include, but are not limited to, bispecific T cell engagers (BiTE), dual-function checkpoint inhibitory T cell engagers (CiTE), synchronous multi-interaction T cell engagers (SMITE), trispecific killer cell engagers (TriKE), chimeric antigen receptor (CAR) T cells expressing BiTE (CART.BiTE cells) or combinations thereof. The present disclosure relates to compositions comprising agonist anti-PD-1 antibodies and bispecific T cell engagers and methods of use thereof. In some preferred embodiments, the agonist anti-PD-1 antibodies and / or antigen-binding fragments disclosed herein and T cell engagers (e.g., bispecific T cell engagers (BiTEs), bifunctional checkpoint inhibitory T cell engagers (CiTEs), synchronized multi-interaction T cell engagers (SMITEs), trispecific killer cell engagers (TriKEs), chimeric antigen receptor (CAR) T cells expressing BiTEs (CART.BiTE cells), and combinations thereof) can be used to treat subjects with cancer. Therefore, the present disclosure relates to a method for treating cancer, comprising administering a therapeutically effective amount of a PD-1 agonist antibody or antigen-binding fragment as disclosed herein and a T cell engager (e.g., bispecific T cell engagers (BiTEs), bifunctional checkpoint inhibitory T cell engagers (CiTEs), synchronized multi-interaction T cell engagers (SMITEs), trispecific killer cell engagers (TriKEs), chimeric antigen receptor (CAR) T cells expressing BiTEs (CART.BiTE cells), and combinations thereof) to a subject in need thereof.
[0289] Additional therapeutic agents that may be used in embodiments include those disclosed in US Pat. No. 11,021,540.
[0290] III. Equivalents
[0291] It will be apparent to those skilled in the art that other suitable modifications and adaptations of the methods of the invention described herein will be apparent and may be made using suitable equivalents without departing from the scope of the present disclosure or embodiments. Having now described certain compositions and methods in detail, these compositions and methods will be more clearly understood by reference to the following examples, which are intended to be illustrative only and not limiting.
[0292] IV. Embodiment
[0293] Example 1: hPD-1-HIS binding of 4G9-1 to 4G9-10
[0294] The antibodies 4G9-1 to 4G9-10 listed in Tables 1-2 and 5 were subjected to HIS binding assays with human PD-1 (hPd-1). The assay included the following procedures:
[0295] At 4°C, 100 μl of 10 μg / ml PD1-protein (Acro Biosystems catalog number HM5221) was coated onto the Maxisorpplate overnight. The next morning, the wells were rinsed 1X with PBST and then blocked with 200 μl / well Superblock / 4% BSA for 2 hours. The wells were washed 3X with 1X PBST. Then, 100 μl of Superblock / 4% BSA containing 1-100 μg / ml 4G9-12 was added and kept at room temperature or 4°C for 2 hours overnight. The wells were washed 3X with 1X PBST. 100 μl of biotinylated anti-human IgG (ThermoFisher catalog number A18827) was added to the wells and combined for 1 hour at room temperature according to the manufacturer's recommendations. In some experiments, anti-human IgG-HRP was used directly (signal was still detected).
[0296] The wells were washed 3X with 1X PBST. 100 μl of 1:5000 SA HRP was added to the wells and allowed to bind for 1 hour at room temperature. The wells were washed 3X with 1X PBST and then 3X with 1X PBS. 100 μl of TMB was added to the wells and development was stopped with 2N sulfuric acid. The optical density at 450 nm (OD 450) was determined.
[0297] The results are listed in Table 7.
[0298] Table 7: hPD-1-HIS binding of 4G9 series antibodies
[0299] Antibody hPD-1-HIS binding (OD 450) 4G9-1 0.874 4G9-2 0.453 4G9-3 0.451 4G9-4 0.386 4G9-5 0.383 4G9-6 0.377 4G9-7 0.361 4G9-8 0.346 4G9-9 0.31 4G9-10 0.287
[0300] Example 2: hPD-1-HIS binding of 5C2-1 to 5C2-10
[0301] The HIS binding assay to human PD-1 (hPD-1) was performed for antibodies 5C2-1 to 5C2-10 listed in Tables 3-4 and 6. The optical density at 450 nm (OD 450) was determined according to the protocol given in Example 1.
[0302] The results are listed in Table 8.
[0303] Table 8: hPD-1-HIS binding of 5C2 series antibodies
[0304]
[0305]
[0306] Example 3: Human T cell activation by 4G9-2 and 4G9-12
[0307] The PD-1 agonist activity of antibodies 4G9-2 and 4G9-12 was determined according to the following in vitro procedure. In summary, IFNγ levels in the supernatant were attributed to T cell activation, which was attributed to the PD-1 agonist activity of the antibodies. Antibodies against human immunoglobulin G1 (hIgG1) were used as controls.
[0308] The materials used were human CD4+ / CD45+ / CD25- naive T cells (BioVit, Hicksville, NY); human IFNγ ELISA kit (Invitrogen, catalog number KHC4021); LymphoOne T cell expansion xeno-free medium (Takara, catalog number WK552S); certified enhanced performance fetal bovine serum (Gibco, catalog number 16000-044); Dynabeads human T-activator CD3 / CD28 (Gibco, catalog number 11132D), interleukin-2 (IL-2; PeproTech, catalog number 200-02); round-bottom sterile 96-well plates; and a plate reader for ELISA.
[0309] The following procedures were followed and all procedures until ELISA determination of IFNγ concentration were performed under sterile conditions.
[0310] Human naive CD4 T cells were thawed. The procedure was performed twice, using T cells from different donors each time. The cells were washed twice with PBS and LymphoOne cell culture medium was added. The cells were counted and their concentration in LymphoOne culture medium was adjusted to 1.5 million / mL. IL-2 and anti-CD3 / anti-CD28 coated Dynabeads were added according to the manufacturer's recommendations. Cells (100 μL cells per well) were added to a round-bottom 96-well plate and incubated for 48 hours at 5% CO2 and 37°C. Antibodies were added at a final concentration of 10-50 μg / mL. An equal volume (20 μL) of culture medium was added to untreated (0 μg / mL antibody) wells, and the same amount and concentration of control antibodies were used. The cells were then incubated at 5% CO2 and 37°C for 24 hours, after which they were centrifuged and the supernatant was collected.
[0311] The collected supernatants were subjected to ELISA for IFNγ detection according to the manufacturer's protocol, with pre-dilutions of the supernatants ranging from 1:1 to 1:50. The IFNγ concentrations determined by ELISA are shown in Figure 1A and 1B middle.
[0312] Figure 1A and Figure 1B It was shown that IFNγ produced by T cells was essentially the same for each donor in the absence of antibody or at any tested concentration of control anti-hIgG1 antibody. Cells were incubated with 4G9-2 or 4G9-12 at a concentration of 10-50 μg / mL, resulting in an increase of about 75-125% in IFNγ production by donor 1 and about 25-65% in IFNγ production by donor 2. The increase in IFNγ production by donor 2 showed a dose-dependent response to both antibodies. The results showed that 4G9-2 and 4G9-12 acted as PD-1 agonists, resulting in increased T cell activation ( ) compared to T cell activation in cells not treated with agonist anti-PD-1 antibodies. Figure 1A and Figure 1B ).
[0313] Example 4: Human T cell activation by affinity matured antibodies 4G9-1 to 4G9-10
[0314] The affinity-matured antibodies 4G9-1 to 4G9-10 were assayed for PD-1 agonist activity essentially as described in Example 3. Briefly, human CD4 + T cells were isolated from donors and stimulated with anti-CD3 / anti-CD28 coated beads and IL-2 for 24 hours. After 24 hours, cells were treated with antibodies selected from 4G9-1 to 4G9-10, a control antibody (4G9HC4-LC1) of the original 4G9 CDR without affinity maturation, or left untreated. After another 48 hours of culture, supernatants were collected and tested for IFNγ production by ELISA. For each treatment, the experiment was performed in duplicate wells. Data from one representative experiment is shown in Figure 2 Compared with the non-affinity matured 4G9 control antibody (4G9 HC4-LC1, see Figure 2 , upper dashed line) and cells not treated with the antibody ("untreated", lower dashed line), IFNγ production by the 4G9-2 antibody was significantly (*p<0.05) higher. Treatment with the 4G9-2 antibody resulted in the highest IFNγ production compared to all other anti-PD1 agonist antibodies tested in the experiment.
[0315] Example 5: Evaluation of 4G9-12 antibody on T memory cell induction and T cell depletion in human T cells
[0316] Essentially as described in Example 3, beads coated with anti-CD3 and anti-CD28 antibodies (DYNABEADS TM GIBCO (THERMO FISHER SCIENTIFIC INC.) and IL-2 (100U / mL-R&D SYSTEMS, INC.) stimulate human CD4 + T cells (BIOIVT LLC). After 72 hours of stimulation, cells were treated with 4G9-12 anti-PD-1 agonist antibody (25 μg / mL) or left untreated (control). After 48 hours of anti-PD-1 agonist antibody treatment, cells were collected, washed, and stained with fluorophore-labeled antibodies. The stained cells were analyzed by flow cytometry. Figure 3A A schematic diagram of the experiment is shown. Central memory T cells (Tcm) were defined as CD45RO 高 / CD62L 高 / CD45RA 低 Exhausted T cells (e.g., terminal effector T cells (Tte)) are defined as CD45RO 低 / CD62L 低 / CD45RA 高 . Relative to total CD4 + T cells, treatment with 4G9-12 resulted in a significant increase in the Tcm population (*p<0.05) and a significant decrease in the Tte population (*p<0.05) (see Figure 3B and Figure 3C ).
[0317] Example 6: Comparison of 4G9-12 and blocking anti-PD-1 antibodies in human T cells
[0318] The aim of this study was to test the expression of primary human CD4 + T cell activation. In purified human CD4 + 4G9-12-mediated T cell stimulation was assessed in T cells. T cells were pre-stimulated with human anti-CD3 / anti-CD28 Dynabeads and IL-2 at 37°C for 24 hours essentially as described in Example 3. After the priming step, cells were exposed to different concentrations of 4G9-12, 4G9-2, isotype control (Iso Ctrl), or blocking anti-PD-1 (PROMEGA Co., clone J1201 ("Blocking-1," Figure 4A , Figure 4B and Figure 4C ) or pembrolizumab (“block-2”, Figure 4C) antibody) for 48 hours, and the level of IFN-γ was determined by ELISA (see Figure 4A-4C ). Although blocking anti-PD-1 antibodies did not increase IFN-γ levels in supernatants from purified CD4 T cells compared with levels observed in supernatants of untreated cells ( Figure 4A-4C ), but 4G9-12 and 4G9-2 treatment resulted in a similar concentration-dependent increase in IFN-γ. The results show that T cell stimulation assessed by the production of IFN-γ is induced by the agonist anti-PD-1 antibodies disclosed herein, but not by antibodies that bind to PD-1 and inhibit interaction with PD-L1 (such as J1201 and pembrolizumab).
[0319] Example 7: Functional evaluation of agonist antibody activity in the presence of PD-L1 or PD-1-blocking antibodies
[0320] The ability of 4G9-2 antibody to activate human CD4 T cells pre-stimulated (24 hours) with CD3 / CD28-coated Dynabeads and IL-2 was tested essentially as described in Example 3, but in the absence or presence of plate-bound PD-L1 as an Fc fusion protein (PD-L1-IgG). Figure 5 As shown, after 72 hours of exposure to 25 μg / mL of 4G9-2, IFN-γ levels in the supernatant increased by >3-fold (measured using ELISA from THERMO FISHER SCIENTIFIC Inc.) compared to untreated T cells or T cells exposed to a blocking anti-PD-1 antibody (PROMEGA Co., clone J1201 "Blocking Ab", 25 μg / mL), confirming that 4G9-2 activated T cells. Although pretreatment of cells with plate-bound PD-L1 (PD-L1-IgG) inhibited IFN-γ production, addition of 4G9-2 treatment in the presence of plate-bound PD-L1 (PD-L1-IgG) resulted in T cell activation comparable to that of 4G9-2 alone, indicating that agonist antibodies (such as 4G9-2) can activate T cells even in the presence of a natural ligand (PD-L1).
[0321] Example 8: Evaluation of potential anti-PD-1 agonist antibodies competing with PD-L1
[0322] To evaluate whether anti-PD-1 agonist antibodies compete with PD-L1 for binding to PD-1 or can bind to PD-1 simultaneously with PD-L1, flow cytometry was used to assess the potential competitive binding of 5 μg / mL APC-labeled 4G9-12 with V450-labeled human PD-L1-IgG (1, 2, or 5 μg / mL) in Raji PD-1+ cells. PD-L1 alone binds to PD-1, and higher binding is observed when PD-L1 concentration increases, as shown in Figure 2. Fig. 6A As shown (PDL1 fluorescence). Figure 6B (4G9-12 fluorescence) and Figure 6C (PD-L1 fluorescence) shows that both 4G9-12 and PD-L1-IgG are able to bind to the target simultaneously, and increasing the concentration of PD-L1-IgG does not affect the binding of 4G9-12. These data also show that PD-L1-IgG maintains the same level of binding in the presence of 4G9-12. These data confirm that PD-1 agonist antibodies (such as 4G9-12) do not compete with PD-L1 for binding to PD-1, so their agonist activity is not attributed to inhibition of PD-L1 binding.
[0323] Example 9: Evaluation of intraperitoneal administration of 4G9-12 antibody in a syngeneic colorectal cancer mouse tumor model
[0324] The antitumor activity of 4G9-12 was evaluated in vivo using a syngeneic colorectal cancer (CRC) tumor model in BALB / c mice. On day 0, mice were injected subcutaneously (SC) with CT26 tumor cells (1x10 5 cells / mouse), and 4G9-12 (0.5 or 1 mg / kg) or a commercially available benchmark PD-1 blocking antibody that is not a PD-1 agonist (clone RMP1-14 (BioXCell, 1 mg / kg)) was administered via intraperitoneal (IP) injection at 10, 13, 16, and 20 days after tumor implantation (0, 3, 6, and 10 days after dosing). A group of tumor-engrafted mice that were not dosed with antibody was used as a negative control group. Tumor volume was monitored. Both doses of 4G9-12 produced significant antitumor activity compared to the untreated control group and the 1 mg / kg PD-1 blocking antibody group. There was no significant difference between the 0.5 and 1 mg / kg doses of 4G9-12, suggesting that at these doses, the antitumor activity reached a plateau response (see Figure 7 The volume of individual tumors in each mouse is shown in Figure 8A-8D This study demonstrated the antitumor activity of 4G9-12 in a mouse model of colorectal cancer and that the agonist antibody had better antitumor activity than the PD-1 blocking antibody.
[0325] Example 10: Evaluation of intravenous administration of 4G9-12 antibody in a syngeneic colorectal cancer mouse tumor model
[0326] The antitumor activity of 4G9-12 was evaluated in vivo using a syngeneic colorectal cancer (CRC) tumor model in BALB / c mice. On day 0, mice were injected subcutaneously with CT26 tumor cells (1x10 5 Cells / mouse) and were administered 4G9-12 (0.01, 0.05, 0.1, or 0.25 mg / kg) or a commercially available benchmark PD-1 blocking antibody (clone RMP1-14, BioXCell; 1 mg / kg, non-agonist antibody) via intravenous (IV) injection on days 14, 18, 22, and 25 after tumor implantation (days 0, 4, 8, and 11 after dosing). A group of tumor-engrafted mice not dosed with antibody was used as a negative control group. Tumor volume was monitored in all mice. All doses of 4G9-12 resulted in statistically significant inhibition of tumor growth compared to untreated controls, with doses of 4G9-12 ≤0.1 mg / kg having similar responses to each other and to 1 mg / kg of anti-PD-1 blocking antibody (see Fig. 9 The volume of individual tumors in each mouse is shown in Figures 10A-10F The benchmark PD-1 blocking antibody (4-fold higher concentration) had lower activity compared to 0.25 mg / kg 4G9-12. This study demonstrated the anti-tumor activity of agonist anti-PD-1 antibodies such as 4G9-12 administered IV in a mouse model of CRC. These data show that the agonist anti-PD-1 antibody 4G9-12 has enhanced tumor growth inhibition compared to PD-1 blocking (e.g., non-agonist) antibodies.
[0327] Example 11: Ex vivo evaluation of T cell activation by anti-PD-1 agonist antibodies in the CT 26 tumor model
[0328] The antitumor activity of 4G9-12 was evaluated in vivo using the CT26 tumor model in BALB / c mice. CT26 cells (1x10 5 ) were implanted into the right flank of BALB / c mice. Ten days after tumor implantation, when the tumor diameter reached 4-6 mm, mice were treated with a single dose of 4G9-12 (1 mg / kg), PD-1 blocking antibody (RMP1-14 clone, 1 mg / kg, non-agonist antibody), or left untreated. Three days after treatment, mice were euthanized and tumors were isolated. Tumors were processed and flow cytometry was used to assess CD4 + and CD8 + The activation state of T cells. CD40L is used as CD4 + CD25 is used as an activation marker for T cells and CD8 +These data show that agonist anti-PD-1 antibodies (such as 4G9-12) but not blocking anti-PD-1 antibodies induce tumor-infiltrating CD4 + and CD8 + In contrast to blocking anti-PD-1 antibodies, 4G9-12 induced tumor-infiltrating CD4 + and CD8 + T cell activation (see Fig.11A and Fig. 11B ).
[0329] Example 12: Assessment of Cell Signaling and T Cell Activation
[0330] To determine whether the intracellular signals transduced by PD-1 differ when PD-1 is bound to agonist antibodies (such as 4G9-12, PD-L1 ligand, and anti-PD-1 blocking antibodies), human CD4 T cells were stimulated with anti-CD3 / anti-CD28 Dynabeads and IL-2 essentially as described in Example 3. + T cells. After stimulation, cells were treated with 25 μg / ml of 4G9-12, PD-L1-IgG (R&D SYSTEMS, INC.) or anti-human PD-1 (clone J1201, PROMEGA Co., non-agonist antibody) for 30 minutes. After 30 minutes of treatment, cells were washed and lysed, and protein A was used for immunoprecipitation, followed by Western blot analysis of ITK, SHP2 and PD-1 (see Fig. 12A and Fig. 12B ). The ratio of ITK / SHP2 (normalized to the level of PD-1) was determined and showed that 4G9-12 resulted in a 3-fold increase in the ITK / SHP2 ratio compared to anti-PD-1 blocking antibody. As expected, PD-L1-IgG treatment resulted in a decrease in the ITK / SHP2 ratio (see Fig. 12C Of particular note, 4G9-12 treatment increased the ITK / SHP2 ratio compared to a control anti-human PD-1 blocking antibody, suggesting that agonist antibodies such as 4G9-12 induce signaling through PD-1 that is distinct from signaling induced by PD-L1.
[0331] Example 13: Through human CD4 + Flow cytometric analysis of cell signaling in T cells with blocking and agonist anti-PD-1 antibodies
[0332] Since ITK is an important molecule in the mechanism of action of agonist PD-1 antibodies, flow cytometry was used to evaluate the effect of 4G9-12 on ITK phosphorylation when compared with blocking anti-PD-1 antibodies (e.g., non-agonist antibodies) pembrolizumab ("Pembro") and nivolumab ("Nivo"). Human CD4+T cells were stimulated with anti-CD3 / anti-CD28 Dynabeads and IL-2 for 24 hours, and then treated with 25 μg / mL of 4G9-12, PD-L1-IgG (R&D SYSTEMS, INC.), pembrolizumab, nivolumab, or not treated ("Stim") for 24 hours. At the end of the treatment, the cells were washed, fixed, permeabilized, and prepared for flow cytometry by staining with Live / Dead stain and PE-labeled anti-phospho-ITK antibody. PD-L1-IgG treatment reduced the phosphorylation of ITK. In contrast to the PD-1 blocking antibodies pembrolizumab and nivolumab, 4G9-12 significantly increased phospho-ITK levels compared with untreated (“Stim”) cells (see Fig.13 These results provide a basis for how treatment with agonist antibodies, such as 4G9-12, can lead to T cell activation, since ITK is an activating molecule in the T cell receptor signaling pathway.
Claims
1. An antibody or antigen-binding fragment thereof having binding specificity to programmed cell death receptor protein 1 (PD-1), comprising a light chain variable region and a heavy chain variable region, wherein the antibody or antigen-binding fragment comprises: CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-1; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-4; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-5; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-6; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-7; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-8; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-9; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-10; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-1; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-2; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-3; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-4; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-5; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-6; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-7; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-8; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-9; or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-10.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment comprises: CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-4; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-8; CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-9; or CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 5C2-8.
3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment comprises: CDR L1, CDR L2, CDR L3, CDR H1, CDR H2 and CDR H3 of 4G9-12.
4. An antibody or antigen-binding fragment thereof having binding specificity to programmed cell death receptor protein 1 (PD-1), comprising a light chain variable region and a heavy chain variable region, wherein a) the light chain variable region comprises QX 8 X 9 X 10 X 11 X 12 CDR L1, containing X 13 X 14 CDR L2 of S and containing X 15 QX 16 X 17 X 18 X 19 PX 20 X 21 The heavy chain variable region comprises a CDR L3 comprising GYTFTTYG (SEQ ID NO: 394), a CDR H1 comprising INTYSGVP (SEQ ID NO: 395), and a CDR H2 comprising ARX 1 X 2 X 3 X 4 X 5 X 6 X 7 CDR H3, where X 1 Selected from the group consisting of G and V; X 2 Selected from the group consisting of G, S, L, V, I and E; X 3 Selected from the group consisting of R, G, P, W, S, H and K; X 4 Selected from the group consisting of G, E, S, V, W and K; X 5 Selected from the group consisting of I, F, S, G, D and V; X 6 Selected from the group consisting of A, G, Y and S; X 7 Selected from the group consisting of Y, H and D; X 8 Selected from the group consisting of G, S and D; X 9 Selected from the group consisting of I and L; X 10 Selected from the group consisting of S, V, G and R; X 11 Selected from the group consisting of N, Y, T, S and R; X 12 Selected from the group consisting of S, Y, D and W; X 13 Selected from the group consisting of A, K, Y and D; X 14 Selected from the group consisting of A and V; X 15 Selected from the group consisting of Q, M and L; X 16 Selected from the group consisting of S, G and D; X 17 Selected from the group consisting of Y, T, N and S; X 18 Selected from the group consisting of S, H and D; X 19 Selected from the group consisting of T, W and F; X 20 is selected from the group consisting of Y, P, R and W; and X 21 Selected from the group consisting of T and F; or b) the light chain variable region comprises QX 42 X 43 X 44 X 45 X 46 CDR L1, containing X 47 AS CDR L2 and containing X 48 X 49 X 50 X 51 X 52 X 53 X 54 CDR L3, and the heavy chain variable region comprises a GX 22 TFX 23 X 24 YX 25 (SEQ ID NO: 163), CDR H1 containing IX 26 X 27 X 28 X 29 X 30 X 31 T CDR H2 and containing AX 32 X 33 X 34 X 35 X 36 X 37 X 38 X 39 FX 40 X 41 CDRH3, where X 22 Selected from the group consisting of Y and Q; X 23 Selected from the group consisting of N, T and G; X 24 Selected from the group consisting of S, I and N; X 25 Selected from the group consisting of W and L; X 26 Selected from the group consisting of H, L, R and P; X 27 Selected from the group consisting of P and L; X 28 Selected from the group consisting of R, S, I and N; X 29 Selected from the group consisting of G, D, N and Y; X 30 Selected from the group consisting of I, S, G and R; X 31 Selected from the group consisting of H, D and Y; X 32 Selected from the group consisting of P and S; X 33 Selected from the group consisting of S, R, N and Y; X 34 Selected from the group consisting of S, D, G, V and F; X 35 Selected from the group consisting of S, N, G, I, D and R; X 36 Selected from the group consisting of Y, N, C, L, S and H; X 37 Selected from the group consisting of A, G, T and E; X 38 Selected from the group consisting of W, C, S, R, D and G; X 39 Selected from the group consisting of A, S, G and D; X 40 Selected from the group consisting of A, S and L; X 41 Selected from the group consisting of H, Y and S; X 42 Selected from the group consisting of D, S and G; X 43 Selected from the group consisting of V and I; X 44 Selected from the group consisting of S and G; X 45 Selected from the group consisting of T and S; X 46 Selected from the group consisting of A, S, D and W; X 47 Selected from the group consisting of W, G and D; X 48 Selected from the group consisting of Q and H; X 49 Selected from the group consisting of Q, K and H; X 50 Selected from the group consisting of H, Y, F, R, D and G; X 51 Selected from the group consisting of Y, N, Y, D, S and G; X 52 Selected from the group consisting of R, S, V, T and I; X 53 is selected from the group consisting of S, A, F, T, Y and W; and X 54 Selected from the group consisting of P, L, S and T.
5. The antibody or antigen-binding fragment thereof of any one of the preceding claims, wherein the antibody or antigen-binding fragment comprises: the light chain variable region and heavy chain variable region of 4G9-12; the light chain variable region and heavy chain variable region of 4G9-1; the light chain variable region and heavy chain variable region of 4G9-2; the light chain variable region and heavy chain variable region of 4G9-3; the light chain variable region and heavy chain variable region of 4G9-4; the light chain variable region and heavy chain variable region of 4G9-5; the light chain variable region and heavy chain variable region of 4G9-6; the light chain variable region and heavy chain variable region of 4G9-7; the light chain variable region and heavy chain variable region of 4G9-8; The light chain variable region and heavy chain variable region of 4G9-9; the light chain variable region and heavy chain variable region of 4G9-10; the light chain variable region and heavy chain variable region of 4G9-11; the light chain variable region and heavy chain variable region of 4G9-13; the light chain variable region and heavy chain variable region of 4G9-14; the light chain variable region and heavy chain variable region of 4G9-15; the light chain variable region and heavy chain variable region of 4G9-16; the light chain variable region and heavy chain variable region of 4G9-17; the light chain variable region and heavy chain variable region of 4G9-18; the light chain variable region and heavy chain variable region of 4G9-19; the light chain variable region and heavy chain variable region of 4G9-20; the light chain variable region and the heavy chain variable region of 5C2-1; the light chain variable region and heavy chain variable region of 5C2-2; the light chain variable region and heavy chain variable region of 5C2-3; the light chain variable region and heavy chain variable region of 5C2-4; the light chain variable region and the heavy chain variable region of 5C2-5; the light chain variable region and heavy chain variable region of 5C2-6; the light chain variable region and the heavy chain variable region of 5C2-7; the light chain variable region and the heavy chain variable region of 5C2-8; The light chain variable region and the heavy chain variable region of 5C2-9; or The light chain variable region and heavy chain variable region of 5C2-10.
6. The antibody or antigen-binding fragment thereof according to claim 1 or 4, wherein the antibody or antigen-binding fragment comprises: the light chain variable region and heavy chain variable region of 4G9-12; the light chain variable region and heavy chain variable region of 4G9-2; the light chain variable region and heavy chain variable region of 4G9-4; the light chain variable region and heavy chain variable region of 4G9-8; The light chain variable region and heavy chain variable region of 4G9-9; the light chain variable region and heavy chain variable region of 4G9-14; the light chain variable region and heavy chain variable region of 4G9-18; The light chain variable region and the heavy chain variable region of 4G9-19; or The light chain variable region and heavy chain variable region of 5C2-8.
7. The antibody or antigen-binding fragment thereof according to claim 6, wherein the antibody or antigen-binding fragment comprises: The light chain variable region and the heavy chain variable region of 4G9-12; or The light chain variable region and heavy chain variable region of 4G9-2.
8. The antibody or antigen-binding fragment thereof as claimed in any one of the preceding claims, further comprising a light chain constant region and a heavy chain constant region.
9. The antibody or antigen-binding fragment of claim 8, wherein the heavy chain constant region is an IgG constant region.
10. The antibody or antigen-binding fragment of any one of claims 1 to 9, wherein the antibody or antigen-binding fragment is a PD-1 agonist.
11. The antibody or antigen-binding fragment of any one of claims 1 to 10, wherein the antibody or antigen-binding fragment does not compete with PD-L1 for binding to PD-1.
12. The antibody or antigen-binding fragment of any one of claims 1 to 11, wherein the antibody or antigen-binding fragment increases pITK levels, ITK / SHP2 ratios, or both pITK levels and ITK / SHP2 ratios in a cell when bound to PD-1 on the cell.
13. The antibody or antigen-binding fragment of any one of claims 1 to 12, which induces central memory T cells (Tcm).
14. The antibody or antigen-binding fragment of any one of claims 1 to 13, which inhibits T cell exhaustion.
15. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 and a pharmaceutically acceptable carrier.
16. A method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment of any one of claims 1 to 14, or the pharmaceutical composition of claim 15.
17. The method of claim 16, further comprising administering to the subject one or more additional therapeutic agents.
18. The method of claim 17, wherein the one or more additional therapeutic agents is an immunomodulatory agent.
19. The method of claim 18, wherein the immunomodulator is a checkpoint inhibitor, provided that the checkpoint inhibitor does not inhibit the interaction of PD-1 with PD-L1 or PD-L2.
20. The method of claim 19, wherein the checkpoint inhibitor is an anti-CTLA4 antibody or an antigen-binding fragment thereof.
21. The method of claim 19, wherein the checkpoint inhibitor is an anti-LAG-3 antibody or an antigen-binding fragment thereof.
22. The method of claim 18, wherein the immunomodulator is a T cell engager.
23. A method as claimed in claim 22, wherein the T cell engager is selected from the group consisting of: bispecific T cell engagers (BiTE), bifunctional checkpoint inhibitory T cell engagers (CiTE), synchronized multi-interaction T cell engagers (SMITE), trispecific killer cell engagers (TriKE), chimeric antigen receptor (CAR) T cells expressing BiTE (CART.BiTE cells) and combinations thereof.
24. The method of claim 17, wherein the one or more additional therapeutic agents is a cell therapy.
25. The method of claim 24, wherein the cell therapy is T cell therapy.
26. The method of claim 24, wherein the cell therapy is tumor infiltrating lymphocytes (TIL).
27. The method of claim 24, wherein the cell therapy is an engineered cell therapy selected from the group consisting of engineered TCR therapy, chimeric antigen receptor (CAR) therapy, or a combination thereof.
28. The method of claim 24, wherein the cell therapy is chimeric antigen receptor T cells (CAR-T cells).
29. The method of claim 24, wherein the cell therapy is an engineered TCR T cell (TCR-T cell).
30. The antibody or antigen-binding fragment of any one of claims 1 to 14 for use in treating cancer.
31. An antibody of any one of claims 1 to 14, comprising an antigen binding fragment thereof, for use in the manufacture of a medicament for the treatment of cancer.
32. A method for treating cancer, comprising administering to a subject in need thereof an effective combination comprising a therapeutically effective amount of (i) an antibody or antigen-binding fragment of any one of claims 1 to 14 or a pharmaceutical composition of claim 15, and (ii) a second antibody or antigen-binding fragment thereof that reduces the inhibition of PD-1 by PD-L1.
33. A combination of the antibody or antigen-binding fragment of any one of claims 1 to 14 and a second antibody or antigen-binding fragment thereof that reduces the repression of PD-1 by PD-L1 for use in treating cancer.
34. A combination of an antibody or antigen binding fragment of any one of claims 1 to 14 and a second antibody or antigen binding fragment thereof that reduces the inhibition of PD-1 by PD-L1 for use in the manufacture of a medicament for treating cancer.
35. A method for inducing or enhancing central memory T cells, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment of any one of claims 1 to 14.
36. A method for inhibiting T cell exhaustion, comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antigen-binding fragment of any one of claims 1 to 14.
37. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof of any one of claims 1 to 14.
38. A host cell comprising the polynucleotide of claim 37.
39. The host cell of claim 38, wherein the host cell is a mammalian cell.
